Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

Canadian Intellectual Property Office
An agency of Industry Canada

CA 2965187 A1 2016/04/28

(21) 2 965 187

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) **Date de dépôt PCT/PCT Filing Date:** 2015/05/29
(87) **Date publication PCT/PCT Publication Date:** 2016/04/28
(85) **Entrée phase nationale/National Entry:** 2017/04/19
(86) **N° demande PCT/PCT Application No.:** AU 2015/050293
(87) **N° publication PCT/PCT Publication No.:** 2016/061619
(30) **Priorité/Priority:** 2014/10/21 (US62/066,808)

(51) **Cl.Int./Int.Cl.** ***A61K 38/16*** (2006.01), ***A61K 38/56*** (2006.01), ***A61K 9/06*** (2006.01), ***A61K 9/08*** (2006.01), ***A61P 17/08*** (2006.01), ***A61P 17/12*** (2006.01), ***A61P 43/00*** (2006.01)

(71) **Demandeur/Applicant:**
HEXIMA LIMITED, AU

(72) **Inventeurs/Inventors:**
VAN DER WEERDEN, NICOLE LOUISE, AU;
ANDERSON, MARILYN ANNE, AU

(74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) **Titre : PROCEDE DE TRAITEMENT**
(54) **Title: A METHOD OF TREATMENT**

(57) **Abrégé/Abstract:**
The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2016 (28.04.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/061619 A1

(51) International Patent Classification:
A61K 38/16 (2006.01) *A61P 17/08* (2006.01)
A61K 38/56 (2006.01) *A61P 17/12* (2006.01)
A61K 9/06 (2006.01) *A61P 43/00* (2006.01)
A61K 9/08 (2006.01)

(21) International Application Number:
PCT/AU2015/050293

(22) International Filing Date:
29 May 2015 (29.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/066,808 21 October 2014 (21.10.2014) US

(71) Applicant: **HEXIMA LIMITED** [AU/AU]; LIMS2, La Trobe University, Bundoora, Victoria 3086 (AU).

(72) Inventors: **VAN DER WEERDEN, Nicole Louise**; Unit 3, 44 Berry Street, Coburg, Victoria 3058 (AU). **ANDERSON, Marilyn Anne**; 25 Garden Avenue, Keilor, Victoria 3036 (AU).

(74) Agent: **DAVIES COLLISON CAVE**; 1 Nicholson Street, Melbourne, Victoria 3000 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

WO 2016/061619 A1

(54) **Title**: A METHOD OF TREATMENT

(57) **Abstract**: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.

A METHOD OF TREATMENT

FILING DATA

[0001] This application is associated with and claims priority from US Provisional Patent Application No. 62/066,808, filed on 21 October, 2014, entitled "A method of treatment", the entire contents of which, are incorporated herein by reference.

BACKGROUND

FIELD

[0002] The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.

DESCRIPTION OF RELATED ART

[0003] Bibliographic details of the publications referred to by author in this specification are collected alphabetically at the end of the description.

[0004] Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

[0005] Fungal infection including infestation can lead to significant health issues in humans and animals.

[0006] Although chemical fungicides have been successful in human and veterinary

medicine, there is a range of environmental and regulatory concerns with the continued use of chemical agents to control fungal infection. The increasing use of these agents is also providing selective pressure for emergence of resistance in fungal species. There is clearly a need to develop alternative mechanisms of controlling infection in humans and animals by fungal pathogens.

[0007] A particularly troublesome condition is onychomycosis, also known as dermatophytic onychomycosis and tinea ungium (Rapini *et al.* (2007) *Dermatology*:2-volume set, St. Louis: Mosby). This is a fungal infection of the nail and other horn-like envelopes covering dorsal and terminal phalanges in humans and animals. In particular, it is an infection of the toenail or fingernail involving any component of the nail unit including the matrix, bed or plate. The disease in humans is not uncommon but can be difficult to treat since the infecting fungus is embedded within and underneath the nail. While not life threatening, onychomycosis can cause pain, discomfort, disfigurement and produce both physical and psychological damage. The effects of onychomycosis are widespread and have a significant impact of the quality of life.

[0008] The major pathogens that cause onychomycosis are the dermatophytes *Tricophyton rubrum* and *Trichophyton mentagrophytes*, with *T. rubrum* accounting for 90% of cases (Sotiriou *et al.* (2010) *Acta Derm-Venereol 9(2)*:216-217).

[0009] The treatment of onychomycosis depends on the clinical subtype, the number of affected nails and the severity of nail involvement. While oral drugs have been most effective, there are a number of factors that prevent their use. Side effects, including hepatotoxicity associated with systemic exposure to most oral antifungal medications, make oral medications unappealing. Furthermore, the elderly are a large demographic that suffer from onychomycosis and unwanted drug-drug interactions due to frequent use of concomitant medications preclude the use of oral medications. This highlights the importance for the development of topical therapies to treat onychomycosis. Most treatments involve either topical or oral antifungal formulations (Westerberg *et al.* (2013) *American Family Physician 88(11)*:762-770). Oral medicaments include terbinafine, itraconazole and fluconazole (Westerberg *et al.* (2013) *supra*). These treatments only cure

infections in 14-38 % of cases and come with a high risk of liver damage. Topical medicaments include ciclopirox, clotrimazole, amorolfine, efinaconazole, tavaborole and butenafine. These treatments have cure rates of between 5 and 17% and must be applied every day for at least 48-weeks. These low cure rates are a result of very poor permeation of the active ingredients through nails as well as fungistatic modes of action which only inhibit fungal growth rather than killing the fungal cells, allowing a reservoir of fungus to persist and re-infect the nail. In addition, the long treatment regimens result in non-compliance by many patients. None of these treatments is totally effective and the condition can persist for many years.

[0010] For a topical onychomycosis treatment to reach the site of infection the antifungal agent must be able to permeate the nail. Studies of permeation of the human nail plate and of keratin membranes from bovine hooves by several model antimycotic drugs showed that nail permeability decreases as molecular weight increases (Mertin and Lippold (1997) *J Pharm Pharmacol 49*:866-872; Kobayashi *et al* (2004) *Eur J Pharm Sci 21*:471-477). Each of the model drugs tested had a molecular weight of less than 1000. These studies suggest that a molecule with a MW > 5000 would not be able to permeate the nail.

[0011] Another problematic condition is fungal infection of hair and other keratin comprising material including the interface between the hair and hair follicle. This condition is sometimes known as tinea capitis or scalp ringworm. Treatment can be in the form of oral medicaments including griseofulvin, terbinafine and itraconazole. Topical treatments include shampoos containing antifungal agents such as ketoconazole, cyclopirox, piroctone and zinc pyrithione. Fungal infections of the scalp and skin can also cause irritation and flaking of the skin leading to conditions such as seborrheic dermatitis and dandruff. Shampoos containing antifungal agents can be used to treat dandruff caused by fungal infection.

[0012] Plant defensins are small (45-54 amino acids), basic proteins with four to five disulfide bonds (Janssen *et al.* (2003) *Biochemistry 42(27)*:8214-8222). They share a common disulfide bonding pattern and a common structural fold, in which a triple-stranded, antiparallel β-sheet is tethered to an α-helix by three disulfide bonds, forming a

cysteine-stabilized αβ motif. A fourth disulfide bond also joins the N- and C-termini leading to an extremely stable structure. Plant defensins can have many biological functions, including anti-bacterial activity, protein synthesis inhibition, α-amylase and protease inhibition, roles inflower development and pollen sensing and antifungal activity (Colilla *et al.* (1990) *FEBS Lett 270(1-2)*:191-194; Bloch and Richardson (1991) *FEBS Lett 279(1)*:101-104; van der Weerden et al (2013) *Fungal Biol Rev 26*:121-131). .

[0013] The structure of defensins consists of seven 'loops', defined as the regions between cysteine residues. Loop 1 encompasses the first β-strand (1A) as well as most of the flexible region that connects this β-strand to the α-helix (1B) between the first two invariant cysteine residues. Loops 2, 3 and the beginning of 4 (4A) make up the α-helix, while the remaining loops (4B - 7) make up β-strands 2 and 3 and the flexible region that connects them (β-hairpin region) [van der Weerden *et al.* (2013) *Cell Mol Life Sci 70 (19)*: 3545-3570]. Loop 5 of plant defensins is known to be essential for antifungal activity and an important determinant for the mechanism of action of these proteins (Sagaram *et al.*, (2011) *PLoS One 6.4*: e18550).

[0014] Plant defensins generally share eight completely conserved cysteine residues. These residues are commonly referred to as “invariant cysteine residues”, as their presence, location and connectivity are conserved amongst defensins. Based on sequence similarity, plant defensins can be categorized into different groups. Within each group, sequence homology is relatively high whereas inter-group amino acid similarity is low (van der Weerden *et al.* (2013) *Fungal Biol Rev 26*:121-131). Plant defensins belonging to different groups have generally different biological activities or different mechanisms of action for the same biological activity. For example, plant defensins belonging to the group of the radish peptide RsAFP2 inhibit fungal growth by binding to sphingolipids in the cell wall (Thevissen *et al.* (2012) *Mol Microbiol 84(1)*:166-180). In contrast, plant defensins belonging to the group of the *Nicotiana* defensin NaD1 inhibit fungal growth by entering the fungal cell and inducing production of reactive oxygen species (ROS) leading to cell lysis (Hayes *et al.* (2013) *Antimicrob Agents Ch 57(8)*3667-3675).

[0015] There are two major classes of plant defensins. Class I defensins consist of an

endoplasmic reticulum (ER) signal sequence followed by a mature defensin domain. Class II defensins are produced as larger precursors with C-terminal pro-domains or pro-peptides (CTPPs) of about 33 amino acids. Most of the Class II defensins identified to date have been found in *Solanaceous* plant species.

[0016] There is a need to develop protocols to more effectively manage fungal infection in humans and animals and in particular, onychomycosis in humans, for which until the advent of the present invention, no safe and effective treatments were available. Whilst some defensins have antifungal properties, their activities across different fungal pathogens vary significantly and a majority of demonstrated activity has been toward plant fungal pathogens. In addition, their size (MW > 5000Da) would appear to limit their permeability into the nails.

SUMMARY

[0017] Amino acid sequences are referred to by a sequence identifier number (SEQ ID NO). The SEQ ID NOs correspond numerically to the sequence identifiers <400>1 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 1. A sequence listing is provided after the claims.

[0018] The present disclosure is predicated in part on the surprising determination that, despite their size, some defensins are able to effectively penetrate nails and treat fungal infection. In addition, despite evolving to target plant fungal pathogens, some plant defensins have potent activity against the fungal pathogens that cause onychomycosis such as *Trichophyton rubrum* with no off-target activity on mammalian cells. More surprisingly, some plant defensins have a fungicidal mode of action enabling them to kill fungal cells on contact. The present disclosure teaches, therefore, a method for inhibiting infection by a fungal pathogen in or on a horn-like envelope covering dorsal and terminal phalanges or a related cerebral protrusion in a subject or keratin comprising material on the subject, the method comprising contacting the envelope or protrusion or keratin comprising material with an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof, the plant defensin, derivative or variant having the consensus amino acid sequence as set forth in SEQ ID NO:24. In an embodiment, the defensin is selected from the group consisting of HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3). Other defensins contemplated herein are selected from the group consisting of HXL001 (SEQ ID NO:4), HXL002 (SEQ ID NO:5), HXL003 (SEQ ID NO:6), HXL004 (SEQ ID NO:7), HXL005 (SEQ ID NO:8), HXL009 (SEQ ID NO:9), HXL012 (SEQ ID NO:10), HXL013 (SEQ ID NO:11), HXL015 (SEQ ID NO:12), HXL032 (SEQ ID NO:13), HXL033 (SEQ ID NO:14), HXL034 (SEQ ID NO:15), NsD1 (SEQ ID NO:16), NsD2 (SEQ ID NO:17), NaD1 (SEQ ID NO:18), NoD173 (SEQ ID NO:19) DmAMP1 (SEQ ID NO:20), HXP4 (SEQ ID NO:21); HXP34 (SEQ ID NO:22), HXP35 (SEQ ID NO:23), and any of the above with an added N-terminal alanine residue (SEQ ID NO:25 through 47, respectively), and a plant defensin having at least about 80% amino acid sequence similarity to any one of SEQ ID NO:1 through 47 after optimal alignment. The defensin contacts generally by topical application the horn-like envelope

or keratin comprising material for a time and under conditions sufficient to eradicate or otherwise control fungal growth. The envelope includes finger and toe nails as well as claws, hooves and horns. In an embodiment, the present disclosure enables a method for the treatment of onychomycosis or a related condition in a subject, the method comprising administering to the subject an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof, the plant defensin or variant having the consensus amino acid sequence as set forth in SEQ ID NO:24. In an embodiment, the defensin is selected from the group consisting of SEQ ID NO:1 through 3 or any one of SEQ ID NO:4 through 47 or a defensin having at least about 80% similarity to any one of SEQ ID NO:1 through 47. In a particular embodiment, the defensin is any one of HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) or HXL036 (SEQ ID NO:3) or a functional natural or synthetic variant thereof including the defensin comprising N-terminal alanine residue (SEQ ID NO:25 though 27 respectively)

[0019] In another embodiment, the keratin comprising material is hair or fur. In this embodiment, the present disclosure enables a method for the treatment of fungal infection of hair or fur in a subject, the method comprising administering to the subject an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof, the plant defensin or variant selected having the consensus amino acid sequence as set forth in SEQ ID NO:24. In an embodiment, the defensin is selected from the group consisting of SEQ ID NO:1 through 3 or any one of SEQ ID NO:4 through 47 or a defensin having at least about 80% similarity to any one of SEQ ID NO:1 through 47. In a particular embodiment the defensin is selected from SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a functional natural or synthetic variant thereof including the defensin comprising N-terminal alanine residue (SEQ ID 25 though 27 respectively).In another embodiment, the keratin comprising material is skin. In this embodiment, the present disclosure enables a method for the treatment of fungal infection of skin in a subject, the method comprising administering to the subject an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof, the plant defensin or variant selected having the consensus amino acid sequence as set forth in SEQ ID NO:24. In an embodiment, the defensin is selected from the group consisting of SEQ ID NO:1 through 3 or any one of SEQ ID NO:4 through 47 or a defensin having at least about 80% similarity

to any one of SEQ ID NO:1 through 47. In a particular embodiment the defensin is defined by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a functional natural or synthetic derivative or variant thereof including the defensin comprising N-terminal alanine residue (SEQ ID 25, though 27 respectively).

[0020] The defensins contemplated for use in the treatment protocol are listed in Table 2 as well as defensins having at least 80% similarity to any one of the defensins listed in Table 2 after optimal alignment. For the sake of brevity, reference to "SEQ ID NO:1 through 47" hereinafter includes defensins having at least 80% similarity to any one of SEQ ID NO:1 through 47. In an embodiment, the defensin is a permeabilizing defensin or a functional natural or synthetic derivative or variant thereof. Examples of synthetic variants include where a Loop1B from a Class I defensin replaces the Loop1B from the *Solanaceous* Class II defensin. These are HXP4, HXP34, and HXP35. Other variants or derivatives include a defensin listed in Table 2 or having at lest 80% similarity to a defensin listed in Table 2 wherein the defensin comprises an alanine residue at its N-terminus (i.e., SEQ ID NO:25 through 47). The addition of an alanine at the N-terminus of a defensin allows the peptide to be produced recombinantly in the *Pichia pastoris* expression system without the need for the STE13 protease site. The STE13 site normally allows for efficient processing of the α-mating factor secretion signal by KEX2. However, under high expression loads the STE13 protease cleavage can be inefficient leading to Glu-Ala repeats remaining on the N-terminus of the peptide. The additional negative charge conferred by these repeats can be detrimental to the activity of plant defensins. The STE13 protease site can be replaced with an alanine to prevent incomplete processing (Cabral *et al.*, (2003) *Protein Expres Purif 31(1)*:115-122). The presence of an N-terminal alanine can also decrease the ability of the defensin to lyse red blood cells (WO 2011/16074).

[0021] In an embodiment, a defensin listed in Table 2 (SEQ ID NO:1 through 47) is modified to enhance the stability of the peptide. In a further embodiment, this is achieved by replacing amino acids that are susceptible to deamidation such as asparagine and glutamine, or amino acids that are susceptible to isomerization such as aspartic acid, with amino acids that are not susceptible to modifications. In a particular embodiment, the defensins HXL008, HXL035 or HXL036 are modified at positions 18, 36 or 42.

[0022] In an embodiment, a defensin listed in Table 2 (SEQ ID NO:1 through 47) is modified to increase the positive charge of the peptide. Positive charge is known to be important for the activity of antimicrobial peptides, including plant defensins (Sagaram *et al.*, (2011) *PLoS One 6.4*: e18550). In an embodiment the increase in positive charge is achieved by replacement of a negatively charged residue such as glutamatic acid or aspartic acid with a neutral amino acid. In an embodiment, the neutral amino acid is an alanine or a glycine. In another embodiment, the increase in positive charge is achieved by replacing a neutral amino acid with a positively charged residue such as lysine or arginine.

[0023] Conservative amino acid changes are also contemplated herein.

[0024] In an embodiment, the treatment includes a defensin in combination with a non-defensin peptide, a proteinase inhibitor, another defensin or a proteinaceous or non-proteinaceous (i.e., chemical) fungicide.

[0025] The fungal pathogen is one which contributes to onychomycosis or related condition in finger or toe nails, claws, hooves or horns in a subject.

[0026] Reference to a "nail" includes any horn-like envelope covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions (i.e., horns) in animals. An "onychomycosis-related condition" is an infection in surrounding cuticle of the nail of a human, non-human primate or animal or an infection in or on a claw, hoof or horn-like protrusion in an animal. An example of a related condition is tinea.

[0027] Fungal pathogens include dermatophytes, yeasts and non-dermatophytic molds. Dermatophytes encompasses *Trichophyton* species, including *Trichophyton rubrum*, *Trichophyton mentagrophytes, Trichophyton interdigitale*, *Trichophyton violaceum*, *Trichophyton tonsurans* and *Trichophyton soudanense*, *Microsporum fulvum*, *Epidermophyton floccosum* and *Microsporum gypseum*. Yeasts encompass *Candida* species including *Candida albicans* and *Candida glabrata*.

[0028] In an embodiment, the defensin is topically applied to the infected region and penetrates the nail or horn-like structure to accumulate at the site of infection. It is surprisingly determined that some defensins such as but not limited to HXL008 (SEQ ID

NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3), have a high degree of penetrability through nails and are potent fungicidal inhibitors of dermatophyte pathogens, and non-dermatophyte molds thus making them very effective in the treatment of conditions such as onychomycosis. In an embodiment the defensins have no off-target effects on mammalian or bacterial cells. Activity against mammalian cells will increase the likelihood of dermal irritation and other side effects. Activity against bacterial cells can disrupt the natural, beneficial microflora in the area. It is well known that the native microflora play an important role in preventing fungal infections (Reid *et al.*, (2011) *Nature Reviews Microbiology 9*: 27-38).

[0029] Further taught herein is a formulation or extract including a plant extract or yeast extract (e.g. an extract of *Pichia* genetically modified to produce a defensin) comprising a plant defensin selected from SEQ ID NO:1 through 47. The formulation or extract may further comprise another active agent or a combination of formulations or extracts wherein at least one formulation or extract comprises a defensin as defined herein which are admixed prior to use or used sequentially in either order. The plant defensins or extracts comprising same as defined herein may be used such as in the form of herbal formulations and natural body or nail washes and shampoos including drenches. The defensin is generally formulated to permit penetration into the target site (e.g. nail or skin or hair or fur strand).

[0030] Enabled herein is a use of a plant defensin as defined by SEQ ID NO:1 through 47 in the manufacture of a medicament for the treatment or prophylaxis of fungal infection of a horn-like envelope covering dorsal and terminal phalanges or related cerebral protrusions in a subject. Also taught herein is a plant defensin as defined by SEQ ID NO:1 through 47 for use in the treatment or prophylaxis of fungal infection of a horn-like envelope covering dorsal and terminal phalanges or related cerebral protrusions in a subject. Enabled herein is a use of a plant defensin as defined by SEQ ID NO:1 through 47 in the manufacture of a medicament for the treatment or prophylaxis of fungal infection of keratin comprising material on a subject. Also taught herein is a plant defensin as defined by SEQ ID NOs:1 through 47. In a particular embodiment, the defensin is defined by the consensus sequence SEQ ID NO:24 or a functional natural or synthetic variant thereof. Examples include

defensins defined by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 as well as the defensin comprising N-terminal alanine residue (SEQ ID 25, though 27 respectively).

[0031] In an embodiment, the fungal infection leads to onychomycosis or a related condition.

[0032] Generally, the subject treated is a human with onychomycosis or a related condition of finger nails or toe nails. However, the present invention also relates to treating animal finger and toe nails, claws and, where applicable, horns, such as in non-human primates, farm animals and horned animals.

[0033] Further contemplated herein is an isolated microorganism engineered to express a defensin as defined herein for use in the manufacture of compositions comprising the microorganisms. An example of a microorganism is *Pichia*. Such compositions are useful in the treatment of humans and animals. Alternatively, the defensin is provided as a cell extract including a plant extract or microbial extract.

[0034] A kit for treating a fungal infection in compartmental form comprising a plant defensin or a functional natural or synthetic derivative or variant thereof, the plant defensin or variant selected from the list consisting of SEQ ID NO:1 through 47, is also taught herein. In an optional embodiment, another compartment comprises a second active agent and optionally separably in a further compartment or together in an existing compartment, a pharmaceutically or veterinarily acceptable diluent, carrier or excipient. In an embodiment, the defensin is defined by the consensus amino acid sequence set forth in SEQ ID NO:24. Examples include HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3).

[0035] In an embodiment, a defensin contemplated for use herein may or may not comprise an N-terminal alanine residue. This is particularly the case with some recombinant defensins which comprise the N-terminal alanine residue. Encompassed by the definition of a "defensin" herein is any of SEQ ID NO:1 though 23 with an N-terminal alanine, i.e. SEQ ID NO:25 through 47. The consensus amino acid sequence, SEQ ID NO:24, has an optional -terminal alanine residue.

TABLE 1

Summary of sequence identifiers

SEQUENCE ID NO:	DESCRIPTION
1	Amino acid sequence of HXL008 protein
2	Amino acid sequence of HXL035 protein
3	Amino acid sequence of HXL036 protein
4	Amino acid sequence of HXL001 protein
5	Amino acid sequence of HXL002 protein
6	Amino acid sequence of HXL003 protein
7	Amino acid sequence of HXL004 protein
8	Amino acid sequence of HXL005 protein
9	Amino acid sequence of HXL009 protein
10	Amino acid sequence of HXL012 protein
11	Amino acid sequence of HXL013 protein
12	Amino acid sequence of HXL015 protein
13	Amino acid sequence of HXL032 protein
14	Amino acid sequence of HXL033 protein
15	Amino acid sequence of HXL034 protein
16	Amino acid sequence of NsD1 protein
17	Amino acid sequence of NsD2 protein
18	Amino acid sequence of NaD1 protein
19	Amino acid sequence of NoD173 protein
20	Amino acid sequence of DmAMP1 protein
21	Amino acid sequence of HXP4 protein
22	Amino acid sequence of HXP34 protein
23	Amino acid sequence of HXP35 protein
24	Consensus sequence
25	Amino acid sequence of HXL008 protein + N-terminal alanine
26	Amino acid sequence of HXL035 protein + N-terminal alanine

SEQUENCE ID NO:	DESCRIPTION
27	Amino acid sequence of HXL036 protein + N-terminal alanine
28	Amino acid sequence of HXL001 protein + N-terminal alanine
29	Amino acid sequence of HXL002 protein + N-terminal alanine
30	Amino acid sequence of HXL003 protein + N-terminal alanine
31	Amino acid sequence of HXL004 protein + N-terminal alanine
32	Amino acid sequence of HXL005 protein + N-terminal alanine
33	Amino acid sequence of HXL009 protein + N-terminal alanine
34	Amino acid sequence of HXL012 protein + N-terminal alanine
35	Amino acid sequence of HXL013 protein + N-terminal alanine
36	Amino acid sequence of HXL015 protein + N-terminal alanine
37	Amino acid sequence of HXL032 protein + N-terminal alanine
38	Amino acid sequence of HXL033 protein + N-terminal alanine
39	Amino acid sequence of HXL034 protein + N-terminal alanine
40	Amino acid sequence of NsD1 protein + N-terminal alanine
41	Amino acid sequence of NsD2 protein + N-terminal alanine
42	Amino acid sequence of NaD1 protein + N-terminal alanine
43	Amino acid sequence of NoD173 protein + N-terminal alanine
44	Amino acid sequence of DmAMP1 protein + N-terminal alanine
45	Amino acid sequence of HXP4 protein + N-terminal alanine
46	Amino acid sequence of HXP34 protein + N-terminal alanine
47	Amino acid sequence of HXP35 protein + N-terminal alanine

[0036] Amino acid sequences for HXL proteins are recited in US Patent No. 6,911,577 and related patent family members.

TABLE 2

Examples of plant defensins

Peptide	Source	Type (Class I, Class II or variant)	Reference
HXL008	*Picramnia pentandra*	Class I	SEQ ID NO:1
HXL035	*Picramnia pentandra*	Class I	SEQ ID NO:2
HXL036	*Picramnia pentandra*	Class I	SEQ ID NO:3
HXL001	*Zea mays*	Class I	SEQ ID NO:4
HXL002	*Triticum aestivum*	Class I	SEQ ID NO:5
HXL003	*Triticum aestivum*	Class I	SEQ ID NO:6
HXL004	*Nicotiana benthamiana*	Class I	SEQ ID NO:6
HXL005	*Taraxcum kok-saghyz*	Class I	SEQ ID NO:7
HXL009	*Zea mays*	Class I	SEQ ID NO:8
HXL012	*Amaranthus retroflexus*	Class I	SEQ ID NO:10
HXL013	*Glycine max*	Class I	SEQ ID NO:11
HXL015	*Oryza sativa*	Class I	SEQ ID NO:12
HXL032	*Triticum aestivum*	Class I	SEQ ID NO:13
HXL033	*Parthenium argentatum*	Class I	SEQ ID NO:14
HXL034	*Nicotiana benthamiana*	Class I	SEQ ID NO:15
NsD1	*Nicotiana*	Class II	SEQ ID NO:16

Peptide	Source	Type (Class I, Class II or variant)	Reference
	suaveolens		
NsD2	*Nicotiana suaveolens*	Class II	SEQ ID NO:17
NaD1	*Nicotiana alata*	Class II	SEQ ID NO:18
NoD173	*Nicotiana occidentalis spp obliqua*	Class II	SEQ ID NO:19
DmAMP1	*Dahlia merckii*	Class I	SEQ ID NO:20
HXP4	Artificial	Variant	SEQ ID NO:21
HXP34	Artificial	Variant	SEQ ID NO:22
HXP35	Artificial	Variant	SEQ ID NO:23
Consensus			SEQ ID NO:24
HXL008 + Ala	Artificial	Variant	SEQ ID NO:25
HXL035 + Ala	Artificial	Variant	SEQ ID NO:26
HXL036 + Ala	Artificial	Variant	SEQ ID NO:27
HXL001 + Ala	Artificial	Variant	SEQ ID NO:28
HXL002 + Ala	Artificial	Variant	SEQ ID NO:29
HXL003 + Ala	Artificial	Variant	SEQ ID NO:30
HXL004 + Ala	Artificial	Variant	SEQ ID NO:31
HXL005 + Ala	Artificial	Variant	SEQ ID NO:32
HXL009 + Ala	Artificial	Variant	SEQ ID NO:33
HXL012 + Ala	Artificial	Variant	SEQ ID NO:34
HXL013 + Ala	Artificial	Variant	SEQ ID NO:35
HXL015 + Ala	Artificial	Variant	SEQ ID NO:36
HXL032 + Ala	Artificial	Variant	SEQ ID NO:37
HXL033+ Ala	Artificial	Variant	SEQ ID NO:38
HXL034 + Ala	Artificial	Variant	SEQ ID NO:39

Peptide	Source	Type (Class I, Class II or variant)	Reference
NsD1 + Ala	Artificial	Variant	SEQ ID NO:40
NsD2 + Ala	Artificial	Variant	SEQ ID NO:41
NaD1 + Ala	Artificial	Variant	SEQ ID NO:42
NoD173 + Ala	Artificial	Variant	SEQ ID NO:43
DmAMP1 + Ala	Artificial	Variant	SEQ ID NO:44
HXP4 + Ala	Artificial	Variant	SEQ ID NO:45
HXP34 + Ala	Artificial	Variant	SEQ ID NO:46
HXP35 + Ala	Artificial	Variant	SEQ ID NO:47

BRIEF DESCRIPTION OF THE FIGURES

[0037] Figures 1(a) through (e) are representations of alignments of amino acids of the various defensins encompassed herein.

[0038] Figures 2(a) through (d) are graphical representations showing the effect of the plant defensins NaD1 (dashed line) and HXL008 (solid line) on the growth of four clinical isolates of *Trichophyton rubrum in vitro*. Fungal growth was measured by the increase in optical density at 595 nm (A595) achieved 72 hours after inoculation of the growth medium and is plotted as a percentage of growth relative to a no-protein control (vertical axis) versus protein concentration (μg/mL, horizontal axis).

[0039] Figures 3(a) through (e) are photographic representations of surviving colonies of *T. rubrum* grown on agar plates after treatment with 100 μM HXL008 for 72 h. Panels (a) to (d) represent clinical isolates 14-01, 14-02, 14-03 and 13-04, respectively. Surviving colonies are marked with a black rectangle. Panel (e) represents the growth of T. rubrum that has not been treated with HXL008.

[0040] Figure 4(a) through (c) are representations of surviving colonies of *T. rubrum* after daily dosing with HXL008. Figure 4a is a photograph of colonies surviving on ½ Sabouraud dextrose agar (SDA) after daily treatment with 0 μg/mL (left panels), 10 μg/mL (middle panels) or 50 μg/mL (right panels) HXL008. Plates are from cultures treated for 24 h (top panels), 14 d (middle panels) or 25 d (lower panels). Figure 4b is a graphical representation of the number of colonies surviving in 100 μL of culture after daily treatment with HXL008 (50 μg/mL/day). Figure 4c is a photograph of the cultures in the absence (left) or presence of 10 μg/mL (middle) or 50 μg/mL (right) of HXL008.

[0041] Figure 5 is a representation of the penetration of nails by HXL008 (black triangles, solid black line), NaD1 (black stars, solid black line), HXL004, (dotted circles, dashed black line), HXL012 (grey square, dashed grey line), tavaborole (black diamond, black dashed line), ciclopirox (dotted square, solid black line) and efniaconazole (grey circles, solid grey line) using a nail adapter system with a wetted-cotton bud acting as the receptor solution underneath the nail.

[0042] Figure 6 is a representation of the growth of *Escherichia coli* in the presence of varying concentrations of the plant defensins NaD1(♦ dotted line), HXL004 (● dashed line) and HXL008 (▲ dashed line) . The human antimicrobial peptide LL37 (■ dotted line) was used as a control.

[0043] Figure 7 is a representation of the permeabilization of human U937 cells by rNaD1, HXP4, HXL001, HXL002, HXL004, HXL005,HXL008, HXL009, HXL012 and HXL013 (10 μM). Permeabilization was measured by monitoring uptake of the fluorescent dye propidium iodide (PI).

[0044] Figure 8 is a representation of the lysis of red blood cells induced by HXL008, HXL004 and NaD1 measured relative to a water control.

[0045] Figure 9 is a representation of nail penetration over time by HXL008 in different formulations, water (black bars) 50mM citrate buffer pH 4.0 (striped bars) and 50mM citrate buffer pH 4.0, 20% v/v ethanol, 0.5mM EDTA (grey bars)

[0046] Figures 10 (a) to (c) are representations of SDS-PAGE, RP-HPLC and mass spectrometry analysis of purified HXL008+ala. Figure 10(a) is an SDS-PAGE gel of purified HXL008+ala. Lanes 1, 2 and 14 are molecular weight markers (SeeBlue® Plus 2). Lanes 3 and 4 are HXL008+ala standard (5 μg) . Lanes 5 to 12 are samples from the pooled size exclusion fractions. Figure 10(b) is a RP-HPLC trace of the pooled elutions. A single peak is observed at ~7.1 mins. Figure 10(c) is a MALDI-TOF mass spectrometry trace from 4 kDa to 20 kDa.

[0047] Figure 11 is a representation of an amino acid alignment of HXL008, HXL035 and HXL036 and a consensus sequence generated by the alignment. Identical amino acids are highlighted in black Conserved amino acids are highlighted in grey.

DETAILED DESCRIPTION

[0048] Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or method step or group of elements or integers or method steps but not the exclusion of any element or integer or method step or group of elements or integers or method steps.

[0049] As used in the subject specification, the singular forms "a", "an" and "the" include plural aspects unless the context clearly dictates otherwise. Thus, for example, reference to "a defensin" includes a single defensin, as well as two or more defensins; reference to "an agent" includes single agent, as well as two or more agents; reference to "the disclosure" includes a single and multiple aspects taught by the disclosure; and so forth. Aspects taught and enabled herein are encompassed by the term "invention". All such aspects are enabled within the width of the present invention. All variants and derivatives or the various aspects are encompassed by the term "form" of the invention.

[0050] Reference to a "defensin" means one of the following plant defensins which retains antifungal activity:

(i) a defensin having the consensus amino acid sequence as set forth in SEQ ID NO:24;

(ii) a defensin selected from the group consisting of HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3);

(iii) a defensin selected from the group consisting of HXL001 (SEQ ID NO:4), HXL002 (SEQ ID NO:5), HXP35 (SEQ ID NO:3), HXL003 (SEQ ID NO:6), HXL004 (SEQ ID NO:7), HXL005 (SEQ ID NO:8), HXL009 (SEQ ID NO:9), HXL012 (SEQ ID NO:10), HXL013 (SEQ ID NO:11), HXL015 (SEQ ID NO:12), HXL032 (SEQ ID NO:13), HXL033 (SEQ ID NO:14), HXL034 (SEQ ID NO:15), NsD1 (SEQ ID NO:16), NsD2 (SEQ ID NO:17), NaD1 (SEQ ID NO:18), NoD173 (SEQ ID NO:19), DmAMP1 (SEQ ID NO:20), HXP4 (SEQ ID NO:21), HXP34 (SEQ ID NO:22) and HXP35 (SEQ ID NO:23);

(iv) a functional naturally occurring or synthetic derivative or variant of any one

of SEQ ID NO:1 through 47;

(v) a defensin having at least 80% similarity to any one of SEQ ID NO:1 through 47 after optimal alignment;

(vi) any one of SEQ ID NO:1 through 47 comprising a N-terminal alanine residue (i.e. SEQ ID NO:25 through 47); and/or

(vii) a defensin having at least 80% similarity to any one of SEQ ID NO:1 through 3 or after optimal alignment. For convenience, these defensins are encompassed within the consensus amino acid sequence set forth in SEQ ID NO:24.

[0051] In an embodiment, the defensin is defined by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a functional natural or synthetic derivative or variant thereof including a polypeptide having antifungal activity with an amino acid sequence of at least 80% similarity to any one of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 after optimal alignment.

[0052] When a second defensin is used in combination with a first defensin, the second defensin may be any defensin.

[0053] A protocol is described herein which is used to facilitate management of fungal infection including infestation at particular anatomical sites in human and animal subjects. The protocol comprises the use of a plant defensin or a functional natural or synthetic derivative or variant thereof to inhibit or otherwise control the growth of a fungal pathogen on or in horn-like envelopes covering dorsal or terminal phalanges in humans and animals and related cerebral protrusions in horned animals. In an embodiment, the envelope is a finger or toe nail, claw or hoof and the cerebral protrusion is a horn. In an embodiment, the fungal infection leads to onychomycosis. In an embodiment, the defensin has potent fungicidal activity against *Trichophyton rubrum* and no activity or medically acceptable minimal activity against mammalian or bacterial cells. In an embodiment, the defensin has good penetrability of the nail such as a defensin with the consensus amino acid sequence set forth in SEQ ID NO:24. Examples include HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3) or these defensins with a N-terminal alanine residue (SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27, respectively) In an optional

embodiment, the defensin is used in synergistic combination with another antifungal agent. The latter agent includes a non-defensin peptide, a proteinase inhibitor, another defensin and a proteinaceous or non-proteinaceous (chemical) agent with antifungal properties. The protocol also extends to treating fungal infection of keratin comprising material such as skin, hair and fur as well as hair and fur follicles.

[0054] Enabled herein is a method for inhibiting infection by a fungal pathogen on or in a horn-like envelope covering dorsal or terminal phalanges or related cerebral protrusions on a subject, the method comprising contacting the envelope with an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof. In an embodiment, the envelope is a nail, claw or hoof. Hence, taught herein is a method for inhibiting growth of a fungal pathogen on or in a finger nail or toe nail or on an animal claw or hoof, the method comprising contacting the nail or claw or hoof with an effective amount of a plant defensin or a functional natural or synthetic variant or derivative thereof. Generally, the contact is for a time and under conditions sufficient to inhibit growth of the fungal pathogen.

[0055] Taught herein is a method for inhibiting infection by a fungal pathogen on or in keratin comprising material on a subject, the method comprising contacting the material with an effective amount of a plant defensin or a functional natural or synthetic derivative or variant thereof. In an embodiment, keratin comprising material is hair or fur. Hence, taught herein is a method for inhibiting growth of a fungal pathogen on or in hair or fur or hair or fur follicle, the method comprising contacting the hair or fur or hair or fur follicle with an effective amount of a plant defensin or a functional natural or synthetic variant or derivative thereof. Generally, the contact is for a time and under conditions sufficient to inhibit growth of the fungal pathogen.

[0056] In an embodiment, keratin comprising material is skin. Hence, taught herein is a method for inhibiting growth of a fungal pathogen on or in skin, the method comprising contracting the skin with an effective amount of a plant defensin or a functional natural or synthetic variant or derivative thereof. Generally, the contact is for a time and under conditions sufficient to inhibit growth of the fungal pathogen.

[0057] "Fungal inhibition" includes both fungicidic and fungistatic activity, as measured by reduction of fungal growth (or loss of viability) compared to a control. Fungal growth can be measured by many different methods known in the art depending on the fungus. A commonly used method of measuring growth of a filamentous fungus, for example, entails germinating spores in a suitable growth medium, incubating for a time sufficient to achieve measurable growth, and measuring increased optical density in the culture after a specified incubation time. The optical density rises with increased growth. Typically, fungal growth is necessary for pathogenesis. Therefore, inhibition of pathogen growth provides a suitable indicator for protection from fungal disease, i.e. the greater the inhibition, the more effective the protection. Furthermore, the effectiveness of the fungicidal or fungistatic activity can be determined by visual inspection of a nail, claw, hoof or horn or of the hair or fur or hair or fur follicle.

[0058] There is no clear definition for successful treatment of onychomycosis. Mycological cure is often defined as a negative result on both the KOH and culture tests (Elewski *et al.* (2012) Fungal diseases In: Bolognia, Jorizzo, Schaffer eds, *Dermatology* 3rd ed. Philadelphia, PA; Elsevier Saunders; chapter 77).

[0059] The treatment protocol includes prophylaxis (i.e., prevention) of at risk subjects from infection. A subject "at risk" may be a subject in a tropical climate. Hence, "preventing infection" in the present context, means that the human or animal host is treated with the defensin so as to avoid fungal infection or disease symptoms associated therewith or exhibit reduced or minimized or less frequent fungal infection or disease symptoms associate therewith, that are the natural outcome of the host-fungal interactions when compared to the host not exposed to the defensin. That is to say, fungal pathogen infection is prevented or reduced from causing disease and/or the associated disease symptoms (i.e. onychomycosis). Infection and/or symptoms are reduced by at least about 10%, 20%, 30%, 40%, 50, 60%, 70% or 80% or greater as compared to a host not so treated with the protocol taught herein. The percentage reduction can be determined by any convenient means appropriate to the host and fungal pathogen.

[0060] Hence, the action of the defensin is to inhibit fungal pathogen growth, replication,

infection and/or maintenance, amongst other inhibitory activities and/or induce amelioration of symptoms of fungal infection or infestation.

[0061] In an embodiment, the fungal infection results in or is associated with onychomycosis or a related condition.

[0062] Hence, enabled herein is a method for the treatment or prophylaxis of onychomycosis or a related condition in a subject, the method comprising contacting an infected site on the subject with a plant defensin or a functional natural or synthetic derivative or variant thereof for a time and under conditions sufficient to ameliorate the symptoms of onychomycosis.

[0063] Reference to "onychomycosis" includes distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis and *Candida* onychomycosis. Reference to a "condition related to onychomycosis" includes tinea and infection of cuticle tissue surrounding the nail, claw, hoof or horn.

[0064] In an embodiment, the fungal infection is tinea capitis, dandruff or seborrheic dermatitis.

[0065] Hence, enabled herein is a method for the treatment or prophylaxis of tinea capitis, dandruff, seborrheic dermatitis or related condition in a subject, the method comprising contacting the material on the subject with a plant defensin or a functional natural or synthetic derivative or variant thereof for a time and under conditions sufficient to ameliorate the symptoms of fungal infection.

[0066] In an embodiment, the fungal infection is of keratin comprising material.

[0067] Hence, enabled herein is a method for the treatment or prophylaxis of fungal infection of keratin comprising material in a subject, the method comprising contacting the material on the subject with a plant defensin or a functional natural or synthetic derivative or variant thereof for a time and under conditions sufficient to ameliorate the symptoms of fungal infection.

[0068] In relation to the latter embodiment, the keratin comprising material includes skin,

hair or fur or is a hair or fur follicle.

[0069] Hence, taught herein is a method for the treatment or prophylaxis of fungal infection of hair or fur or a hair or fur follicle on a human, the method comprising contacting the hair or fur or hair or fur follicle on the subject with a plant defensin or a functional natural or synthetic derivative or variant thereof for a time and under conditions sufficient to ameliorate the symptoms of fungal infection.

[0070] By "contacting" includes exposure of the fungal pathogen to the defensin following topical administration or application to the human or animal subject. Contact may be with a purified plant defensin or formulation comprising same, or a plant extract which comprises the defensin naturally or which has been engineered to produce the defensin. A formulation includes herbal formulations and extracts such as nail polish and nail wash. Extracts may be derived from plants or a microorganism such as a yeast (e.g., *Pichia*). Hence, the defensin is applied topically to a surface area on the human or animal subject. Reference to "contacting includes the step of administering to a subject or an infected site on a subject.

[0071] In an embodiment, the defensin is formulated in a topical formulation, nail, claw, hoof or horn formulation or body or hair washing solution. A microbial or cell extract comprising the defensin may also be applied. An example is a *Pichia*-derived extract. Topical formulations include an aqueous solution, liquid formulation, solution, drench, tonic, a wash, a spray, paint, a powder, a dispersant, an atomized formulation, cream, ointment, lipstick, gel, sludge, paste, patch, impregnated bandage and the like. Plant extracts comprising the defensin are also contemplated herein including a plant extract comprising the defensin. Generally, the defensin is formulated so as to permit penetration into the target site (e.g., nail, claw, hoof, horn or hair or fur particle). In an embodiment, the defensin is selected based on its penetrability.

[0072] Enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen in or on a horn-like envelope covering a dorsal or terminal phalange or related cerebral protrusion on a human or animal subject.

[0073] Further enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen on a nail, claw, hoof or horn on a human or animal subject.

[0074] Further enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen associated with onychomycosis in a human subject.

[0075] Enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen of keratin comprising material on a human or animal subject.

[0076] Further enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen of hair or fur or a hair or fur follicle on a human or animal subject.

[0077] Enabled herein is a formulation comprising a plant defensin or a functional natural or synthetic derivative or variant thereof for use in inhibiting infection by a fungal pathogen associated with tinea capitis, dandruff or seborrheic dermatitis on a human or animal subject.

[0078] In an embodiment, taught herein is a therapeutic kit comprising a compartment or in compartmental form wherein a compartment comprises a plant defensin or a functional natural or synthetic derivative or variant thereof. Second or further compartments may comprise other agents or excipients including other antifungal agents. The contents of each compartment may be admixed prior to use or used sequentially in any order. Other antifungal agents include non-defensin peptides, a proteinase inhibitor, another defensin or a proteinaceous or chemical (non-proteinaceous) antifungal agent. Examples of other antifungal agents which may be used in combination with the plant defensin include griseofulvin, terbinafine, amorolfine, ciclopirox, efinaconazole, tavaborole and a triazole.

[0079] Reference to a "plant defensin" means those defined herein with reference to Table 2. A defensin from Table 2 may also be selected based on its penetrability of a nail, claw, hoof or horn. A defensin from Table 2 may also be selected based on its potent fungicidal

activity against *T. rubrum* and lack of activity or medically acceptable minimal activity against on mammalian and bacterial cells. As defined herein, a defensin includes a defensin having at least about 80% similarity to SEQ ID NO:24 including any one of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or any one of SEQ ID NO:4 through 47. The 80% similarity is determined after optimal alignment and, where necessary, after appropriate spaces are used to optimize the alignment. By "at least 80%" or "at least about 80%" includes 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100%. A useful defensin in the practice of this invention is a defensin which penetrates readily into the nail. Particular examples include HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3) and variants thereof with an N-terminal alanine residue ((SEQ ID NO:25. (SEQ ID NO:26 and (SEQ ID NO:27 respectively).

[0080] Hence, taught herein is a method for inhibiting infection of a fungal pathogen on a horn-like envelope covering a dorsal or terminal phalange or related cerebral protrusion or keratin comprising material or follicle for the keratin comprising material on a subject, the method comprising contacting the envelope or protrusion or keratin comprising material with an effective amount of plant defensin selected from SEQ ID NO:1 through 47 or a functional natural or synthetic derivative or variant thereof or a defensin having at least 80% similarity to any one of SEQ ID NO:1 through 47 after optimal alignment or a defensin selected from SEQ ID NO:25 through 47 with an N-terminal alanine residue for a time and under conditions sufficient to ameliorate symptoms of the infection.

[0081] Also enabled herein is a method for inhibiting infection of a fungal pathogen on a horn-like envelope covering a dorsal or terminal phalange or related cerebral protrusion or keratin comprising material or follicle for the keratin comprising material on a subject, the method comprising contacting the envelope or protrusion or keratin comprising material with an effective amount of a defensin having the consensus amino acid sequence set forth in SEQ ID NO:24 or a functional natural or synthetic derivative or variant thereof or a defensin having at least 80% similarity to SEQ ID NO:24, optionally with an N-terminal alanine residue for time and under conditions sufficient to amelirorate symptoms of infection.

[0082] Further taught herein is the use of HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) or HXL036 (SEQ ID NO:3) to treat onychomychosis. Also taught is the use of a defensin defined by SEQ ID NO:25, SEQ ID NO:26 or (SEQ ID NO:27 to treat onychomycosis.

[0083] The term "similarity" as used herein includes exact identity between compared sequences at the amino acid level. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In an embodiment, amino acid sequence comparisons are made at the level of identity rather than similarity.

[0084] Terms used to describe sequence relationships between two or more polypeptides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage sequence similarity", "percentage sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 amino acid residues in length. Because two polypeptides may each comprise (1) a sequence (i.e., only a portion of the complete amino acid sequence) that is similar between the two polypeptides, and (2) a sequence that is divergent between the two polypeptides, sequence comparisons between two (or more) polypeptides are typically performed by comparing sequences of the two polypeptides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, Clustal W2 and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul *et al.* (1997) *Nucl. Acids. Res. 25(17):*3389-

3402. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al*. (1994-1998) *In: Current Protocols in Molecular Biology*, John Wiley & Sons Inc. Other alignment software includes BWA (Li and Durbin (2010) *Bioinformatics 26*: 589-595) and Bowtie (Langmead *et al* (2009) *Genome Biol 10*:R25 and BLAT (Kent (2002) *Genome Res 12*:656-664).

[0085] The terms "sequence similarity" and "sequence identity" as used herein refer to the extent that sequences are identical or functionally or structurally similar on an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by any suitable method or computer algorithm using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.

[0086] Some defensins used herein may be referred to herein as a “naturally occurring” defensin, a “modified” defensin, a “variant” defensin, a “mutated” defensin a “synthetic derivative or variant” or a “chimeric” defensin, depending on its source. For the practice of the present invention, such defensins retain antifungal activity.

[0087] In an embodiment, the defensin is a Class II *Solanaceous* defensin. In an embodiment, the defensin is modified at the loop region between the first β-strand (β-strand 1) and the α-helix at the N-terminal end portion of the defensin. In an embodiment, the loop region comprises the 6 amino acids N-terminal of the second invariant cysteine residue or its equivalent. This region is defined as “Loop1B”. A Class II *Solanaceous* defensin is distinguished from other defensins by a relatively conserved C-terminal end

portion of the mature domain.

[0088] Included herein is the use of an artificially created defensin comprising a modified Class II *Solanaceous* defensin backbone wherein the loop region between β-strand 1 and the α-helix on the N-terminal end portion is modified by a single or multiple amino acid substitution, addition and/or deletion to generate a variant defensin which has anti-pathogen activity. In an embodiment, the loop region is Loop1B defined by the 6 amino acid residues N-terminal to the second invariant cysteine residue. Its equivalent region in any defensin is contemplated herein. In an embodiment, the artificially created defensin comprises a modified Class II defensin. The present protocol does not extend to the use of NaD1 comprising its natural amino acid sequence.

[0089] Examples of suitable defensins include those listed in Table 1. These comprise synthetic defensin variants such as HXP4 (SEQ ID NO:21), HXP34 (SEQ ID NO:22) and HXP35 (SEQ ID NO:23). Also encompassed herein are the latter three defensins with an N-terminal alanine residue (i.e. SEQ ID NO:45 through 47, respectively). A useful defensin is HXL008 (SEQ ID NO: 1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3) or a functional natural or synthetic derivative or variant thereof includes SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

[0090] Taught herein is a method for inhibiting infection by a fungal pathogen, on or in a nail, claw, hoof or horn, the method comprising contacting the nail, claw, hoof or horn with an effective amount of a plant defensin selected from the list presented in Table 1 herein or a derivative or variant thereof. Generally, the defensin is applied for a time and under conditions sufficient to ameliorate the symptoms of the infection. In an embodiment, the symptoms are associated with onychomycosis or a related condition.

[0091] Taught herein is a method for inhibiting infection by a fungal pathogen, on or in a nail, claw, hoof or horn, the method comprising contacting the nail, claw, hoof or horn with an effective amount of a plant defensin selected from the list presented in Table 2 herein or a derivative or variant thereof. The defensin may be applied at a concentration of between 0.1% and 10% w/v, at a frequency of once a day, twice a day, once every two days, once a week, once every two weeks or once a month, for a period of four weeks, two

weeks, one week, three weeks, one month, two months, three months or up to 12 months. In an embodiment, the symptoms are associated with onychomycosis or a related condition.

[0092] Taught herein is a method for inhibiting infection by a fungal pathogen, on or in skin, hair or fur, the method comprising contacting the skin, hair or fur or hair or fur follicle with an effective amount of a plant defensin selected from the list presented in Table 1 herein or a derivative or variant thereof. The defensin is applied for a time and under conditions sufficient to ameliorate the symptoms of the infection. In an embodiment, the symptoms are associated with fungal infection.

[0093] Taught herein is a method for inhibiting infection by a fungal pathogen, on or in skin, hair or fur, the method comprising contacting the skin, hair or fur or hair or fur follicle with an effective amount of a plant defensin selected from the list presented in Table 1 herein or a derivative or variant thereof. The defensin may be applied at a concentration of between 0.1% and 10% w/v, at a frequency of once a day, twice a day, once every two days, once a week, once every two weeks or once a month, for a period of one week, two weeks, three weeks, one month, two months, three months or up to 12 months. In an embodiment, the symptoms are associated with fungal infection.

[0094] In an optional embodiment, the defensin or its derivative or variant is used in combination with another agent such as an antifungal agent. It is proposed that the defensin and the peptide act in synergy. Examples of other agents include a non-defensin antimicrobial peptide, a proteinase inhibitor another defensin or a proteinaceous or non-proteinaceous chemical fungicide.

[0095] Chemical antifungal agents for use in combination with a subject defensin include terbinafine, intraconazole, fluconazole, ciclopirox, clotrimazole, amorolfine butenafine, tavaborole, efinaconazole, AN2718 and NP213.

[0096] Reference to synergy means that the inhibitory effect of a given defensin or other agent alone is greater when both are used together compared to either used alone. Greco *et al*. (1995) *Pharmacol Rev. 47*:331-385 define a category of synergy on the basis that the

use of two agents in combination has greater activity relative to the additive effects when each is assayed alone. Hence, the definition adopted herein includes all such situations provided that the combined effect of the two agents acting together is greater than the sum of the individual agents acting alone. Furthermore, a combination of agents is deemed synergistic, as the term is intended herein, if there exists a set of conditions, including but not limited to concentrations, where the combined effect of the agents acting together is greater than the sum of the individual components acting alone. Richer (1987) *Pestic Sci 19*:309-315 describes a mathematical approach to establish proof of synergy. This approach uses Limpel's formula for comparing an observed level of inhibition (Io) in the combined presence of two inhibitor agents, X and Y, with an expected additive effect (Ee) resulting from each X or Y acting separately at the same respective concentrations as used to measure their combined effect. Additive percent inhibition, Ee, is calculated as X + Y - XY/100 where X and Y are expressed as percent inhibition. Synergism exits where Io > Ee.

[0097] Synergy may be expressed as a synergy scale. In an embodiment, a value of up to 14 represents no significant synergy such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14; a value of from 15 up to 29 represents low synergy such as 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29; a value of from 30 to 60 represents medium synergy such as 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60; a value greater than 60 represents a high degree of synergy. By "greater than 60" includes from 61 to 100 including 61, 70, 80, 90 and 100 and any value in between.

[0098] The present method is useful in the treatment or prophylaxis of a subject having an infection or infestation by a fungal pathogen of a horn-like envelope covering a dorsal or terminal phalange or related cerebral protrusion or of keratin comprising material such as skin, hair or fur. The term "subject" includes a human of any age or an animal such as a farm animal (e.g., sheep, pig, horse, cow, donkey, camel, llama, alpaca) or poultry bird (e.g., chicken, duck, turkey, pheasant, peacock)), companion animal (e.g., dog or cat), laboratory test animal (e.g., mouse, rat, rabbit, guinea pig or hamster) or captive wild animal (e.g., wild goat). A "human" or "animal" includes a part thereof such as toe nails,

finger nails, claws, hooves, horns, skin, hair or fur.

[0099] Reference to a "fungus" includes dermatophytes, yeasts and non-dermatophytic molds (non-dermatophytes). Dermatophytes include *Trichophyton* species including *Trichophyton rubrum*, *Trichophyton interdigitale*, *Trichophyton violaceum*, *Trichophyton tonsurans*, *Trichophyton soudanense* and *Trichophyton mentagrophytes*, *Microsporum fulvum*, *Epidermophyton floccosum* and *Microsporum gypseum*. Yeasts encompass *Candida* species including *Candida albicans* and *Candida glabrata*, The fungus may cause tinea such as Tinea pedis, dandruff or a dermatitis.

[0100] Another aspect taught herein is a composition comprising a plant defensin or a functional natural or synthetic derivative or variant thereof with one or more pharmaceutically or veterinary acceptable carriers, diluents or excipients for use in treating or preventing onychomycosis or a related condition. In an optional embodiment, the plant defensin is used in combination with a defensin and another antifungal agent. In an embodiment, the composition is in the form of a spray, mist, micro- or nano-particles, an aqueous solution, drench, a wash, a tonic, a dispersant, an atomized formulation, lipstick, sludge, powder, cream, ointment, gel, patch, impregnated bandage, liquid, formulation, paint or other suitable distribution medium including topical forms of the composition. The defensin may be specifically formulated to facilitate penetration of a nail, claw, hoof or horn or hair or fur particle.

[0101] Useful applications include solutions, paints, creams, powders, drops, ointments, shampoos and drenches for fungal infection of nails, claws, hooves or horns or of hair or fur.

[0102] Compositions which comprise the defensin and optionally another antifungal agent described herein, generally include a carrier, excipient, diluent, preservative, stabilizer and/or a solid or liquid additive. Plant extracts comprising the defensin may also be used. A formulation includes a body wash or shampoo or drench.

[0103] The composition may take a wide variety of forms depending on the intended method of administration. Generally, but not exclusively, topical compositions are used

for human or animal subjects. In preparing the compositions, usual media may be employed such as, for example, water, organic acids such as citric acid or acetic acid, glycols such as ethylene glycol, propylene glycol, 1,3-butylene glycol and polyethylene glycol, oils, alcohols such as ethanol, methanol or isopropanol, preservatives and/or coloring agents. The compositions may take the form of a liquid preparation such as, for example, suspensions, elixirs and solutions. Carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may also be used. The composition may also be in the form of a paint, powder, dispersant, ointment, cream or wash.

[0104] The composition may include one or more acceptable excipients such as ethylenediaminetetraacetic acid, cyclomethicone, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl chitosan, polyvinylpyrrolidone, ethyl acetate, diisopropyl adipate, isopropyl myristate and myristyl lactate.

[0105] The defensin is administered directly to the infected site, generally for a time and under conditions sufficient to ameliorate the symptoms of infection. This includes amelioration of the symptoms of onychomycosis or a related condition.

[0106] In an embodiment, the defensin is administered directly to the infected site, at a concentration of between 0.1% and 10% w/v, at a frequency of once a day, twice a day, once every two days, once a week, once every two weeks or once a month, for a period of one week, two weeks, three weeks, one month, two months, three months or up to 12 months.

[0107] When administered by aerosol or spray, the compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons and/or other solubilizing or dispersing agents known in the art.

[0108] The effective dosage of the defensin may vary depending on whether used alone or in a particular combination, the mode of administration, the fungal pathogen being treated

and the severity of the fungal pathogen infestation. Thus, the dosage regimen utilizing the defensin is selected in accordance with a variety of factors including type, species, age, weight, sex and medical disposition of the subject; the severity of the condition to being treated; the mode of administration; and the particular defensin thereof employed. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the defensin required to prevent, counter or arrest the progress of fungal pathogen infestation. Slow release formulations are also contemplated herein. In an embodiment, the composition comprises a penetrant to facilitate entry of the defensin into the site of infection

[0109] In an embodiment, the composition contains a molecule that increases permeation across the nail. Molecules that increase nail permeation include inorganic salts, mercaptan, glycine, cysteine, urea, peroxide, acids such as phosphoric acid or thioglycolic acid, alkalis such as sodium or potassium hydroxide, reducing agents (thiols, sulfites), dimethyl sulfoxide, poly glycols, glycerine, C_{2-5} alcohol, C_{2-8} polyol, C_{6-24} fatty acid triglyceride, C_{6-24} fatty alcohol, C_{6-24} alkyl sulphate, C_{6-24} fatty acid, ;non-ionic surfactant or mixtures thereof (Murthy *et al.* (2009) *J Pharm Sci 98(11)*:4264-4271; Nair *et al. (2009) J Pharm Pharmacol 61(4)*:413-417; Malhotra and Zatz (2002) *J Pharm Sci 91(2)*:312-323; Khengar *et al.* (2007) *Pharm Res 24(12)*:2207-2212; Murdan (2008) *Expert Opin Drug Deliv 5(11)*:1267-1282; Reeves US Patent No. 6,391,879; Willers *et al.* European Patent No. 2664327).

[0110] Another aspect provides a protocol or method for treating or preventing an animal including a mammalian such as a human subject infected or infested with a fungal pathogen, the protocol or method comprising applying to the subject an anti-fungal pathogen effective amount of a composition comprising the plant defensin at a site which is a horn-like envelope covering a dorsal or terminal phalange or related cerebral protrusion or is keratin comprising material.

[0111] Yet another aspect provides a protocol or method for treating or preventing onychomycosis or fungal infection of the skin hair or fur, the protocol or method comprising applying to a nail, claw, hoof, horn or hair or fur particle or hair or fur follicle

an anti-fungal pathogen effective amount of a composition comprising the plant defensin and optionally another antifungal agent. The latter includes a non-defensin antimicrobial peptide, a proteinase inhibitor, another defensin and a proteinaceous or non-proteinaceous chemical antifungal agent.

[0112] The term "applying" includes contacting and exposing as well as administering to a site. In an embodiment, the application includes the act of penetrating the nail, claw, hoof or horn or the act of penetrating a hair or fur particle or hair or fur follicle.

[0113] The defensin is useful for combating a fungal disease or infection of horn-like envelopes and related cerebral protrusions such as nails, claws, hooves and horns or of keratin comprising material such as skin, hair or fur. In an embodiment, the subject specification teaches a protocol for the treatment or prophylaxis of onychomycosis or a related condition. In an embodiment, the subject specification teaches a protocol for the treatment or prophylaxis of tinea capitis, dandruff and seborrheic dermatitis or a related condition. The protocol has human and veterinary applications.

[0114] The present defensin may be manufactured based on its amino acid sequence using standard stepwise addition of one or more amino acid residues using, for example, a peptide or protein synthesizer. Alternatively, the defensin is made by recombinant means. A recombinant defensin may include an additional alanine residue at its N-terminus. Hence, defensins contemplated herein may contain the N-terminus alanine residue.

[0115] Another aspect taught herein is a method for producing the plant defensin recombinantly. In an embodiment, the plant defensin is produced using a microbial expression system. In a further embodiment, the expression system is a yeast-based expression system such as *Pichia pastoris*. In a preferred embodiment, the plant defensin is expressed as a fusion protein with a secretion signal that targets the protein outside the cell. The secretion signal is then removed enzymatically to release mature plant defensin into the expression medium. The plant defensin is then purified by ion-exchange chromatography. In a preferred embodiment, the plant defensin is purified by cation-exchange chromatography using a resin such as SP-Sepharose. The plant defensin is then further purified by size-exclusion chromatography using a medium suitable for small

proteins such as Superdex 30.

[0116] In addition, the defensin may be subject to chemical modification to render the defensin a chemical analog. Such defensin analog, may exhibit greater stability or longer half life at the point of contact with the tissue.

[0117] Analogs contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the defensin molecule. This term also does not exclude modifications of the defensin, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, defensins containing one or more analogs of an amino acid (including, for example, unnatural amino acids) or defensins with substituted linkages. Such analogs may have enhanced stability and/or penetrability.

[0118] Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH4; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH4.

[0119] The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

[0120] The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

[0121] Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride

or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

[0122] Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

[0123] Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

[0124] Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A bifunctional crosslinkers such as the bifunctional imido esters having (CH2)n spacer groups with n = 1 to n = 6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of Cα and N α-methylamino acids, introduction of double bonds between Cα and Cβ atoms of amino acids and the formation of cyclic peptides or analogs by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

[0125] Mimetics are another useful group of defensin analog. The term is intended to refer to a substance which has some chemical similarity to the defensin and mimics its anifungal activity. A peptide mimetic may be a peptide-containing molecule that mimics elements of protein secondary structure (Johnson et al., Peptide Turn Mimetics in Biotechnology and

Pharmacy, Pezzuto et al., Eds., Chapman and Hall, New York, 1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate activity actions.

[0126] Still another aspect provides a method for reducing or controlling fungal infection or infestation on a human nail, the method comprising topically applying a plant defensin or a functional natural or synthetic derivation or variant thereof and optionally another antifungal agent to a potentially infected region on the human. In an embodiment, the medicament is in the form of a solution, powder, spray, atomizer, nanoparticle, gel, paste, impregnated bandage, paint, aerosol, drench or other liquid. The anti-fungal formulation may also be a slow release composition.

[0127] Still another aspect provides a method for reducing or controlling fungal infection or infestation on human hair, the method comprising topically applying a plant defensin or a functional natural or synthetic derivation or variant thereof and optionally another antifungal agent to a potentially infected region on the human. In an embodiment, the medicament is in the form of a solution, powder, spray, atomizer, nanoparticle, gel, paste, impregnated bandage, paint, aerosol, drench or other liquid. The anti-fungal formulation may also be a slow release composition.

[0128] As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any recitation herein of the term "comprising", particularly in a description of components of a composition or in a description of elements of a device, is understood to encompass those compositions and methods consisting essentially of and consisting of the recited components or elements. The present disclosure illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.

[0129] When a Markush group or other grouping is used herein, all individual members of

the group and all combinations and sub-combinations possible of the group are intended to be individually included in the disclosure.

[0130] When a range is recited herein, it is intended that all sub-ranges within the stated range, and all integer values within the stated range, are intended, as if each sub-range and integer value was recited.

EXAMPLES

[0131] Aspects disclosed and enabled herein are now described in the following non-limiting Example.

Methods

Purification of defensins from Pichia Pastoris

[0132] A single pPINK-defensin *P. pastoris* PichiaPink (Trademark) strain 1 colony is used to inoculate 25 mL of BMG medium (described in the Invitrogen *Pichia* Expression Manual) in a 250 mL flask and that is incubated over for 2-3 days in a 30ºC shaking incubator (140 rpm). The culture is used to inoculate 200 mL of BMG in a 1 L baffled flask which is placed in a 30ºC shaking incubator (140 rpm) overnight. The cells are harvested by centrifugation (1,500 x g, 10 min, 4ºC) and resuspended into 1 L of BMM medium in a 5 L baffled flask and incubated in a 28ºC shaking incubator for 3 days (2 days for NaD1). The cultures are induced at t=24 and 48h. The expression medium is separated from cells by centrifugation (6000 rpm, 20 min, 4 ºC). The medium is adjusted to pH 3.0 before it is applied to an SP Sepharose column (1 cm x 1 cm, Amersham Biosciences) pre-equilibrated with 100mM potassium phosphate buffer, pH 6.0. The column is then washed with 100 mL of 100mM potassium phosphate buffer, pH 6.0 (wash x 2 for HXL004). Bound protein is eluted in 10x10 mL of 100mM potassium phosphate buffer containing 500 mM NaCl. A dot blot is performed to identify factions with the highest concentration of eluted protein and those fractions are concentrated down to 1 mL using a centrifugal column and washed 5x using sterile milli Q ultrapure water. The protein concentration of Pichia-expressed defensin is determined using the bicinchoninic acid (BCA) protein assay (Pierce Chemical Co.) with bovine serum albumin (BSA) as the protein standard.

[0133] The defensins contemplated for use herein are listed in Tables 1 and 2 and include defensins having at least 80% similarity to any one of the listed defensins after optimal alignment.

[0134] Figures 1(a) through (e) provide an alignment showing the similarity of amino acid

sequences between (see Table 1 for definitions). Figure 11 provides an alignment of amino acid sequences for HXL008 (SEQ ID NO:1), HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3). This alignment is used to generate consensus amino acid sequence set forth in SEQ ID NO:24. Any of these sequences may contain an optional N-terminal alanine residue.

EXAMPLE 1

Inhibition of the growth of Trichophyton rubrum and Microsporum fulvum in the presence of a plant defensin

[0135] Plant defensins include a *Solanaceous* Class II defensin (NaD1) and Class I defensins (HXL001, HXL002, HXL004, HXL005, HXL008, HXL009, HXL012, HXL013, HXL015, NaD2). See Tables 1 and 2 for the sequence identifiers.

[0136] The inhibitory effects of the plant defensins on the growth of *Trichophyton rubrum, T. interdigitale, Microsporum fulvum* and *C. albicans* (obtained from the National Mycology Reference Centre, South Australia Pathology at the Women's and Children's Hospital, Adelaide, Australia) are measured essentially as described by Broekaert *et al.* (1990) *FEMS Microbiol Lett 69*:55-59.

[0137] Spores of *T. rubrum*, *T. interdigitale* and *M. fulvum* are isolated from sporulating fungus growing on ½ strength Sabouraud dextrose agar (SDA). Spores were removed from the plates by the addition of ½ strength potato dextrose broth (PDB). *C. albicans* cells are grown in Yeast Peptone Broth (YPD) for 16 h. Spore and cell concentrations are measured using a hemocytometer.

[0138] Antifungal assays are conducted in 96 well microtitre plates essentially as herein described. Wells are loaded with 20 μ L of filter sterilized (0.22 μ m syringe filter, Millipore) defensin (10x stock for each final concentration) or water and 80 μ L of 5 x 10^4 spores/mL (*T. rubrum, T, interdigitale, M. fulvum*) or 5,000 cells/mL (*C. albicans*) in ½ strength PDB. The plates are incubated at 30°C. Fungal growth is assayed by measuring optical density at 595nm (A595) using a microtitre plate reader (SpectraMax Pro M2; Molecular Devices. Growth is allowed to proceed until the optical density (OD) of the fungus in the absence of any test defensin reached an OD of 0.2. Each test is performed in duplicate.

[0139] After incubation for 72 h, the media from wells containing clinical isolates of *T. rubrum* incubated with 100 g/mL HXL008 was plated onto fresh Sabouraud dextrose agar. Plates were incubated at 30°C for 5 days to allow colonies to develop before being

photographed.

[0140] The results of the inhibition assays are shown in Table 3. HXL005, HXL008 and HXL035 are the most effective plant defensins across the range of fungal pathogens. HXL001 and HXL009 did not display any activity at the concentrations tested. HXL002 and NaD2 are very poor inhibitors of *M. fulvum* and *C. albicans*. HXL004, HXL012, HXL013 and HXL015 display intermediate activity across the range of pathogens.

[0141] The results of inhibition of clinical isolates of *T. rubrum* by HXL008 (solid line) and NaD1 (dashed line) are shown in Figures 2(a) to 2(d). Both peptides inhibited fungal growth at low concentrations with IC50s of below 20 µg/mL against four clinical isolates. However, in all cases HXL008 inhibited growth at a lower concentration than NaD1.

[0142] The results of cell survival assays for clinical isolates of *T. rubrum* are shown in Figures 3(a) to 3(e). Plates that had been inoculated with cells that had not been incubated with a plant defensin were almost completely covered in growth. In contrast, plates that were inoculated with cells had been incubated in the presence of HXL008 for 72 h only had 1-3 colonies indicating that almost all the cells were dead.

TABLE 3

Defensin	IC_{50} against *T. rubrum* (µg/mL)	IC_{50} against *M. fulvum* (µg/mL)	IC_{50} against *T. interdigitale* (µg/mL)	IC_{50} against *C. albicans* (µg/mL)
HXL001	>100	>100		35
HXL002		50		35
HXL003		>100		>100
HXL004	27.5	12	19	20
HXL005	3	5	3.5	22
HXL008	3	7	3.5	20
HXL009		>100		>100
HXL012	2	18	2	42
HXL013	22	5.5		20
HXL015	10	12.5	3.5	
HXL035	2	2	1	18
NaD2		38		43
NaD1	8	5.3	10	20

EXAMPLE 2

Inhibition of the growth of Trichophyton rubrum over 28 days in the presence of HXL008

[0143] The inhibitory effect of HXL008 on the growth of *Trichophyton rubrum* (obtained from the National Mycology Reference Centre, South Australia Pathology at the Women's and Children's Hospital, Adelaide, Australia) was monitored over 28 days.

[0144] Spores of *T. rubrum*, are isolated from sporulating fungus growing on ½ strength Sabouraud dextrose agar. Spores are removed from the plates by the addition of ½ strength potato dextrose broth (PDB). Spore and cell concentrations are measured using a hemocytometer.

[0145] Spores were diluted to a concentration of 5 x 10^4 spores/mL in ½ PBD (2 mL) containing 0, 10 or 50 µg/mL HXL008. Cultures are incubated at 30 C without shaking. After 24 h, 100 µL of each culture is extracted and plated onto ½ SDA plates. An additional 100 uL of ½ PDB is then added containing either 0, 20 or 100 µg of HXL008. SDA plates are then incubated at 30 C for 5 days. This process is repeated every 24 h for 28 days. After 15 days, the culture containing no HXL008 becomes too thick to pipette and is no longer used in the assay.

[0146] The results of the inhibition assay are presented in Figure 4. Cultures treated with either 10 µg/mL or 50 µg/mL did not display any visible growth of *T. rubrum* over the duration of the assay. Within 24 h, HXL008 at 50 µg/mL had killed more than 80% of *T. rubrum* cells, as visible when plated onto ½ SDA in the absence of HXL008. Over the next 19 days the number of surviving colonies continued to decrease. After 20 days of treatment, plates had either 0 or only 1 colony indicating that more than 99.5% of the cells were dead.

EXAMPLE 3

Penetration of plant defensins through human nails

[0147] Penetration of NaD1 through human nails was measured according to the method of Hui *et al.* (2002) *J Pharm Sci 91(1)*:189-195. Human toenails were obtained from ScienceCare (USA) and washed with phosphate buffered saline (details, PBS) before being placed on a kimwipe that had been soaked in PBS for 3 h to rehydrate the nail. The nail was then placed in a plastic nail adapter with a dosing area of 0.5 x 0.5 cm (Permagear, USA) and a cotton bud wetted with 75 microlitres of PBS was placed in the receptor chamber in contact with the underside of the nail.

[0148] Protein (10-30 µL of 5-10 mg/mL solution) was applied to the top of the nail every 24 h for 4 days. The cotton bud in contact with the underside of the nail was removed after 24 h and every 24 h following. Protein that had passed through the nail was recovered from the cotton bud by washing twice with 500 µL of 0.1% v/v trifluoroacetic acid. Recovered protein was quantified using RP-HPLC.

[0149] The results of the nail penetration assays are represented in Table 4 and Figure 5. When applied daily to the surface of nails, the plant defensins HXL008, NaD1 and HXL004 were able to penetrate nails faster and more effectively than the active ingredients of current topical onychomycosis therapies (tavaborole, efinaconazole and ciclopirox). More HXL008 was detected coming through the nail than NaD1 or HXL004. The plant defensin HXL012 did not penetrate the nail.

TABLE 4

	Cumulative amount through nail (µg)							
Day	**1**	**2**	**3**	**4**	**6**	**9**	**12**	**15**
HXL008 (30 uL of 1% solution, 0.2cm^2 daily application)	83	184	302	453				
	28%	31%	34%	38%				
NaD1 (30 uL of 1% solution, 0.2cm^2 daily application)	32	44	58	75				
	11%	7%	6%	6%				
HXL004 (20 uL of 0.5% solution, 0.2cm^2 daily application)	9	22	30					
	9%	11%	10%					
HXL012 (20 uL of 0.5% solution, 0.2cm^2 daily application)	0	0	0					
	0%	0%	0%					
Tavaborole (10 uL of 10% solution, 0.8cm^2 daily application)			60		220	610	1280	2240
			2.0%		3.7%	6.8%	10.7%	14.9%
Ciclopirox (10 uL of 10% solution, 0.8cm^2 daily application)			1		2	4	6	9
			0.03%		0.03%	0.04%	0.05%	0.06%
Efinaconazole (2 uL of 10% solution, 0.03cm^2 single application)	0.4	0.7	1.3	1.6	2.6	4.0	5.4	6.5
	0.2%	0.4%	0.7%	0.8%	1.3%	2.0%	2.7%	3.3%

EXAMPLE 4

Inhibition of the growth of Escherichia coli in the presence of plant defensins

[0150] A single *E. coli* colony was used to inoculate 5 ml of Luria-Bertani media and grown overnight at 37°C. The following day, the optical density of the culture was measured and the *E. coli* diluted to an optical density at 600 nm (OD_{600}) of 0.01 in Mueller-Hinton Broth. Diluted *E. coli* were added to 96-well plates with defensins at concentrations of 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM or 0.1625 μM. Plates were read at OD_{595} to obtain time zero data points. Plates were incubated at 37°C for 18 hours before reading again at OD_{595} to assess the amount of *E. coli* growth.

[0151] The results of inhibition of *E. coli* is shown in Figure 7. HXL004 inhibited the growth of *E. coli* in a concentration dependent manner, similar to the LL37 control. NaD1 and HXL008 did not inhibit growth of E. coli at the concentrations tested.

EXAMPLE 5

Survival of mammalian cells in the presence of plant defensins

[0152] Human monocytic lymphoma (U937) cells are cultured in RPMI-1640 medium. All culture media are supplemented with 5–10% v/v fetal calf serum, 100 U/ml of penicillin, and 100 μg/ml of streptomycin. Cell lines are cultured at 37°C in a humidified atmosphere containing 5% v/v CO_2. Adherent cell lines are detached from the flask by adding a mixture containing 0.25% v/v trypsin and 0.5 μM EDTA.

[0153] A flow cytometry-based propidium iodide (PI) uptake assay is performed to analyze the ability of plant defensins to permeabilize U937 cells (essentially as described in Poon et al, 2014). Briefly, cells are suspended to 1×10^6 cells/ml in 0.1% v/v BSA/RPMI-1640 and incubated with plant defensins (10 μM) at 37°C for 30 min. Samples are added to PBS containing a final concentration of 1 μg/ml PI and placed on ice. Samples are then analyzed immediately using the BD FACSCanto II Flow Cytometer and BD FACSDiva software v6.1.1. The resultant flow cytometry data is analyzed using FlowJo software v8.8.6. Cells are gated appropriately based on forward scatter and side scatter and cell permeabilization is defined by PI-positive staining.

[0154] The results of the PI-uptake assay are shown in Figure 7. The plant defensins NaD1 and HXL005 are toxic to mammalian cells under the conditions tested. NaD1 permeabilized 33% of cells while HXL005 permeabilized almost 25%. The plant defensins HXP4, HXL004 and HXL013 were less toxic to mammalian cells permeabilising just 13% (HXP4 and HXL004) or 5% (HXL013) of cells. In contrast, HXL001, HXL002, HXL008, HXL009 and HXL012 were not significantly toxic to mammalian cells under the conditions tested, permeabilizing less than 2% of cells.

EXAMPLE 6

Human red blood cell lysis in the presence of plant defensins

[0155] Human red blood cells (RBCs) were collected from whole blood and washed with 1 × PBS and pelleted at 1000 × g for 10 min. RBCs were diluted 1 in 10 for treatment with plant defensins (100 μM) and incubated over-night under a humidified atmosphere of 5% v/v CO2 / 95% v/v air. After 24 h incubation, the cells were centrifuged for 10 min at 2000 rpm, with the supernatant diluted to 1 in 100 with 1 × PBS. Released haemoglobin indicative of RBC lysis was then determined by measuring absorbance at 412 nm. Results have been normalised to RBCs treated with water (designated 100% lysis).

[0156] The results of the red blood cell lysis assay is shown in Figure 8. At 100 μM, the plant defensins NaD1 and HXL004 lysed 1.47 and 1.09 percent of RBCs respectively while HXL008 lysed just 0.42 percent. Error bars represent standard deviation.

EXAMPLE 7

Effect of formulation components on penetration of HXL008 through human nails

[0157] HXL008 was dissolved to a concentration of 10 mg/mL in either water, 50 mM citrate buffer pH 4.0 or 50 mM citrate buffer pH 4.0 containing 20% v/v ethanol and 0.5 mM EDTA. Penetration of HXL008 in each formulation through human nails was measured according to the method of Hui *et al.* (2002) *Supra.* Human toenails were obtained from ScienceCare (USA) and washed with phosphate buffered saline (PBS) before being placed on a kimwipe that had been soaked in PBS for 3 h to rehydrate the nail. The nail was then placed in a plastic nail adapter with a dosing area of 0.5 x 0.5 cm (Permagear, USA) and a cotton bud wetted with 75 microlitres of PBS was placed in the receptor chamber in contact with the underside of the nail.

[0158] Protein in formulation (10 µL of 10 mg/mL solution) was applied to the top of the nail every 24 h for 2 or 3 days. The cotton bud in contact with the underside of the nail was removed after 24 h and every 24 h following. Protein that had passed through the nail was recovered from the cotton bud by washing twice with 500 µL of 0.1% v/v trifluoroacetic acid. Recovered protein was quantified using RP-HPLC.

[0159] The results of the penetration assays are represented in Table 6 and Figure 9. When applied daily to the surface of nails, penetration of HXL008 through the nail was enhanced in the presence of 50mM citrate buffer pH4.0, with or without ethanol and EDTA.

TABLE 6

Penetration of HXL008 in three different formulations through nails

		24 H	48 H	72 H
Water	Dose (µg)	100	100	10(
	Amount in receptor (µg)	10.75	12.1	12.4
	Percent of dose permeated	10.8%	12.1%	12.5%
	Cumulative percent permeated	10.8%	11.4%	11.8%
50 mM Citrate Buffer, pH 4.0	Dose (µg)	100	100	10(
	Amount in receptor (µg)	13.5	41.72	58.6(
	Percent of dose permeated	13.5%	41.7%	58.7%
	Cumulative percent permeated	13.5%	27.6%	38.0%
50 mM Citrate Buffer, pH 4.0, 20% v/v Ethanol, 0.5 mM EDTA	Dose (µg)	100	100	
	Amount in receptor (µg)	18.97	53.33	
	Percent of dose permeated	19.0%	53.3%	
	Cumulative percent permeated	19.0%	36.2%	

EXAMPLE 8

Recombinant expression of plant defensins using P. pastoris

[0160] The plant defensins HXL008, HXL008+ala, HXL004 and NaD1 were expressed in *Pichia pastoris* as described in the Methods.

[0161] The yield for various plant defensins from recombinant expression in *P. pastoris* is shown in Table 7. HXL008+ala was the most highly expressed protein with a yield of 7.5 mg/L.

TABLE 7

Defensin yields following protein expression and purification

Protein	*Protein purified per litre of culture (mg)*
HXL008+ala	7.5
HXL008	6.3
HXL004	1.2
NaD1	3.2

EXAMPLE 9

Large Scale Expression and Purification of HXL008+ala

[0162] The open reading frame (ORF) for HXL008+ala is cloned into the *Pichia* expression vector pPIC9. The ORF is inserted in frame with the α-factor secretion signal and directly downstream of the KEX2 cleavage site. The plasmid is then linearized in the HIS4 selection cassette using the restriction enzyme SalI and transformed into electrocompetent GS115 *Pichia pastoris* cells. Positive colonies are selected using media lacking histidine. Positive colonies are used to inoculate 5mL of YPD and incubated for 25 h at 30ºC in a shaking incubator. Cells in culture are mixed with 20% glycerol, flash-frozen and stored at -80ºC.

[0163] Cells from a glycerol stock are streaked onto YPD plates and allowed to grow at 30ºC for 48 h. Plates are then stored at 4ºC for up to 2 weeks.

[0164] Cells from a YPD plate (pPIC9-defensin, GS115) are used to inoculate 500 mL of BMG medium (described in the Invitrogen *Pichia* Expression Manual) in a 2.5 L flask and the culture is incubated for 2 days in a 28ºC shaking incubator (120 rpm). After 48 h, the culture is used to inoculate 20 L of Fermentation Basal Salts Media in a 30 L B Braun Fermenter. Temperature is maintained at 28ºC over the period of the ferment. The pH is maintained at 5.0 over the period of the ferment by addition of 25% v/v ammonia Solution in response to any decrease in pH. Dissolved oxygen (DO) is maintained at 30% during the fermentation period by increasing the agitation (minimum 500 rpm) or increasing the flow or oxygen.

[0165] The 20 L culture fed sterile 100% v/v glycerol at a rate of 3.6 mL/min until the cell density reaches 250 – 300 g/L. At this time, the glycerol feed is stopped and the culture is allowed to proceed until all the glycerol is consumed, as evidenced by a spike in DO. The culture is then fed sterile 100% v/v methanol containing 12 mL/L trace metals. The feed rate is accelerated over 8 h from 0.2 to 2.18 mL/min. A feed rate of 2.18 mL/min is then continued for an additional 48 h.

[0166] The expression medium is harvested and separated from cells by centrifugation

(6000 rpm, 20 min, 4ºC). The medium is clarified by filtering through a 0.22 µm membrane The medium is diluted 1 in 5 in 50 mM acetate buffer pH 5.3. Diluted medium is then applied to an SP-Sepharose column (High Performance) that has been pre-equilibrated with 50 mM acetate buffer pH 5.3. The column is then washed with 20 column volumes of 50 mM acetate buffer pH 5.3. Bound HXL008 is eluted using a linear gradient of 0-100% v/v 50 mM acetate buffer pH 5.3 containing 1 M NaCl. Fractions containing protein (as identified by absorbance at 280 nm) are pooled and concentrated down to 200 mL before being subjected to size-exclusion chromatography. Proteins are loaded onto a 1800 mL Superdex 30 column (5cm x 92cm XK50/100 column) and eluted using 50 mM sodium phosphate buffer, 150 mM NaCl, pH 7.2 at 15 mL/min. Proteins eluting in the void volume are discarded and fractions containing HXL008+ala are identified using mass spectrometry. Fractions containing HXL008 are pooled and then desalted into sterile MilliQ water and concentrated using a 3000 MWCO spin column.

[0167] The resulting peptide solution was analysed by SDS-PAGE, RP-HPLC and mass spectrometry. The final yield was determined by measuring the peptide concentration using a BCA assay. A total of 1.436 g of HXL008+ala is produced and purified to greater than 99% purity.

[0168] The results of the purification are shown in Figure 10. Figure 10A is an SDS-PAGE gel of purified HXL008+ala. Lanes 1, 2 and 14 are molecular weight markers (SeeBlue [registered trade mark] Plus 2). Lanes 3 and 4 are HXL008+ala standard (5 µg). Lanes 5 to 12 are samples from the pooled size exclusion fractions. Figure 10B is a RP-HPLC trace of the pooled elutions. A single peak is observed at ~7.1 mins which is consistent with the expected retention time for HXL008+ala. Figure XC is a MALDI-TOF mass spectrometry trace from 4 kDa to 20 kDa. The observed mass (5477 Da) corresponds to the expected mas for HXL008+ala with all four disulphide bonds formed.

[0169] Those skilled in the art will appreciate that the disclosure described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure contemplates all such variations and modifications. The disclosure also enables all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of the steps or features or compositions or compounds.

BIBLIOGRAPHY

Altschul *et al.* (1997) *Nucl. Acids. Res. 25:*3389

Ausubel *et al.* (1994-1998) *In: Current Protocols in Molecular Biology*, John Wiley & Sons Inc

Bloch and Richardson (1991) *FEBS Lett 279(1)*:101-104

Broekaert *et al.* (1990) *FEMS Microbiol Lett 69*:55-59

Cabral *et al* (2003) *Protein Express Purif* 31(1):115-122

Colilla *et al.* (1990) *FEBS Lett 270(1-2)*:191-194

Elewski *et al.* (2012) Fungal diseases In: Bolognia, Jorizzo, Schaffer eds, *Dermatology* 3rd ed. Philadelphia, PA; Elsevier Saunders; chapter 77

Greco *et al.* (1995) *Pharmacol Rew 47*:331-385

Hayes *et al.* (2013) *Antimicrob Agents Ch 57(8)*3667-3675

Hui et al (2002) *J. Pharm Sci 9(11)*: 189-195

Janssen *et al.* (2003) *Biochemistry 42(27)*:8214-8222

Johnson et al., Peptide Turn Mimetics in Biotechnology and Pharmacy, Pezzuto et al., Eds., Chapman and Hall, New York, 1993

Kent (2002) *Genome Res 12*: 656-664

Khengar *et al*. (2007) *Pharm Res 24(12)*:2207-2212

Kobayashi *et al* (2004) *Euro J Pharm Sci 21*:471-477

Langmead *et al* (2009) *Genome Biol 10*:R25

Li and Durbin (2010) *Bionformatics 26*:589-595

Malhotra and Zatz (2002) *J Pharm Sci 91(2)*:312-323

Merten and Lippold (1997) *J Pharm Pharmacol 49*: 866-872

Murdan (2008) *Expert Opin Drug Deliv 5(11)*:1267-1282

Murthy *et al*. (2009) *J Pharm Sci 98(11)*:4264-4271

Nair *et al*. *(2009) J Pharm Pharmacol 61(4)*:431-437

Rapini *et al*. (2007) *Dermatology*:2-volume set, St. Louis: Mosby

Reeves US Patent No. 6,391,879

Reid *et al* (2011) *Nature Review & Microbiol 9*: 27-38

Richer (1987) *Pestic Sci 19*:309-315

Sagaram *et al*., (2011) *PLoS One 6.4*: e18550

Sotiriou *et al*. (2010) *Acta Derm-Venereol 9(2)*:216-217

Thevissen *et al*. (2012) *Mol Microbiol 84(1)*:166-180

CLAIMS:

1. A method for inhibiting infection of a fungal pathogen on or in a toe or finger nail, claw, hoof or a horn or keratin-comprising material or follicle for the keratin-comprising material on a subject, said method comprising contacting the toe or finger nail, claw, hoof or horn or keratin-comprising material or the follicle with an effective amount of a toe or finger nail-, claw-, hoof- or horn- or keratin-comprising material penetrating plant defensin having the amino acid sequence: Xaa Lys Val Cys Thr Lys Pro Ser Lys Phe Phe Lys Gly Leu Cys Gly Xaa Asp Xaa Xaa Cys Thr Xaa Ala Cys Xaa Lys Glu Gly Leu Xaa Xaa Gly Xaa Cys Gln Xaa Lys Gly Phe Xaa Asn Xaa Val Cys Val Cys Arg Lys Xaa Cys (SEQ ID NO:24); wherein Xaa at position 1 is an alanine or no residue and Xaa at positions 17, 19, 20, 22, 26, 31, 32, 34, 37, 41, 43 and 50 is any amino acid, for a time and under conditions sufficient to ameliorate symptoms of the infection.

2. The method of Claim 1 wherein the infection is associated with onychomycosis or a related condition.

3. The method of Claim 2 wherein the related condition is tinea or infection of cuticle tissue surrounding the toe or finger nail, claw, hoof or horn.

4. The method of Claim 1 wherein the keratin-comprising material is hair, fur or skin.

5. The method of Claim 1 wherein the defensin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

6. The method of Claim 5 wherein the defensin is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

7. The method of Claim 5 wherein the defensin is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

8. The method of Claim 1 wherein the defensin is used in synergistic combination with an antifungal agent.

9. The method of Claim 8 wherein the antifungal agent is a peptide of from about 0.4 to about 12 kD or a proteinase inhibitor.

10. The method of Claim 8 wherein the antifungal agent is a chemical fungicide selected from terbinafine, intraconazole, fluconazole, ciclopirox, clotrimazole, amorolfine and butenafine.

11-. The method of Claim 1 wherein the fungal pathogen is selected from the group consisting of a dermatophyte, *Candida* species and a non-dermatophyte.

12. The method of Claim 11 wherein the dermatophyte is a *Trichophyton* species selected from the group consisting of *Trichophyton rubrum*, *Trichophyton interdigitale*, *Trichophyton violaceum*, *Trichophyton tonsurans*, *Trichophyton soudanense* and *Trichophyton mentagrophytes*; or is *Microsporum fulvum*, *Epidermophyton floccosum* or *Microsporum gypseum*.

13. The method of Claim 11 wherein the non-dermatophyte is selected from the group consisting of *Neoscytalidium*, *Scopulariopsis, Acremonium, and Scytalidium*.

14. The method of Claim 11 wherein the non-dermatophyte is *Neoscytalidium* or *Scopulariopsis*.

15. A topical formulation or cell or plant extract comprising a plant defensin having the amino acid sequence: Xaa Lys Val Cys Thr Lys Pro Ser Lys Phe Phe Lys Gly Leu Cys Gly Xaa Asp Xaa Xaa Cys Thr Xaa Ala Cys Xaa Lys Glu Gly Leu Xaa Xaa Gly Xaa Cys Gln Xaa Lys Gly Phe Xaa Asn Xaa Val Cys Val Cys Arg Lys Xaa Cys (SEQ ID NO:24); wherein Xaa at position 1 is an alanine or no residue and Xaa at positions 17, 19, 20, 22, 26, 31, 32, 34, 37, 41, 43 and 50 is any amino acid which penetrates a toe or finger nail, claw, hoof or horn or

keratin-comprising method and one or more pharmaceutically or veterinary acceptable carriers, diluents and/or excipients for use in treating onychomycosis or a related condition.

16. The formulation or cell or plant extract of Claim 15 wherein the related condition is tinea.

17. The formulation or cell or plant extract of Claim 15 wherein the keratin-comprising material is hair, fur or skin.

18. The formulation or cell or plant extract of Claim 15 or 16 or 17 wherein the formulation is a body or hair wash or paint, spray, drops, cream or lotion applicator.

19. The formulation or cell or plant extract of any one of Claims 15 to 18 wherein the defensin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

20. The formulation or cell or plant extract of Claim 19 wherein the defensin is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

21. The formulation or cell or plant extract of Claim 19 wherein the defensin is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

22. Use of a formulation or cell or plant extract of any one of Claims 15 to 21 in the manufacture of a medicament for the treatment or prophylaxis of onychomycosis or a related condition in a human or animal subject.

23. Use of Claim 15 wherein the keratin-comprising material is hair, fur or skin.

HXL1	T.aestivum	100.00	SEQ ID NO:4
SbD17	S.bicolor	97.96	SEQ ID NO:48
ZmD9	Z.mays	97.96	SEQ ID NO:49
SolD1	S.officinarum	93.88	SEQ ID NO:50
ObD1	O.brachyantha	81.63	SEO ID NO:51
HXL2	T.aestivum	100.00	SEQ ID NO:5
Ta-PDF30	T.aestivum	97.96	SEQ ID NO:52
TtD4	T.turgidum	97.96	SEQ ID NO:53
Ta-PDF25	T.aestivum	87.76	SEQI D NO:54
TtD1	T.turgidum	85.71	SEQ ID NO:55
Tm-AMP-D1.2	T.urartu	85.71	SEQ ID NO:56
Ta-PDF23	T.aestivum	83.67	SEQ ID NO:57
TaD18	T.aestivum	83.67	SEQ ID NO:58
AtaD3	A.tauschii	82.98	SEQ ID NO:59
Tm-AMP-D1.2	T.urartu	82.98	SEQ ID NO:60
AtaD4	A.tauschii	81.63	SEQ ID NO:61
Ta-PDF13	T.aestivum	81.63	SEQ ID NO:62
TaD15	T.aestivum	81.63	SEQ ID NO:63
rmTAD1	T.aestivum	81.63	SEQ ID NO:64
TtD2	T.turgidum	81.63	SEQ ID NO:65
TtD5	T.turgidum	81.63	SEQ ID NO:66

Figure 1(a)

HXL4	N.benthamiana	100.00	SEQ ID NO:7
J1-2	C.annuum	95.74	SEQ ID NO:67
defensin	N.attenuata	91.49	SEQ ID NO:68
StD15	S.tuberosum	91.49	SEQ ID NO:69
AtD84	A.thaliana	85.11	SEQ ID NO:70
PpD1	P.persica	85.11	SEQ ID NO:71
PpyD3	P.pyrifolia	85.11	SEQ ID NO:72
AhS4	A.halleri	82.98	SEQ ID NO:73
CanD5	C.annuum	82.98	SEQ ID NO:74
CsaD1	C.sativa	82.98	SEQ ID NO:75
Eg-PDF	E.grandis	82.98	SEQ ID NO:76
Lm-PDF	L.michauxii	82.98	SEQ ID NO:77
PvD3	P.vulgaris	82.98	SEQ ID NO:78
SlD17	S.lycopersicum	82.98	SEQ ID NO:79
Tm-PDF	T.majus	82.98	SEQ ID NO:80
BnD9	B.napus	80.85	SEQ ID NO:81
CclD4	C.clementina	80.85	SEQ ID NO:82
CrD10	C.rubella	80.85	SEQ ID NO:83
CrD11	C.rubella	80.85	SEQ ID NO:84
Ct-PDF	C.tetragonoloba	80.85	SEQ ID NO:85
Gm-PDF5	G.max	80.85	SEQ ID NO:86
GmD8	G.max	80.85	SEQ ID NO:87
LjD1	L.japonicus	80.85	SEQ ID NO:88
MtD23	M.truncatula	80.85	SEQ ID NO:89
NaD2	N.alata	80.85	SEQ ID NO:90
NtD4	N.tabacum	80.85	SEQ ID NO:91
ObD2	O.brachyantha	80.85	SEQ ID NO:92
PvD6	P.vulgaris	80.85	SEQ ID NO:93
ScD1	S.chacoense	80.85	SEQ ID NO:94
VuD2	V.unguiculata	80.85	SEQ ID NO:95
Vs-PDF	V.vinifera	80.85	SEQ ID NO:96

Figure 1(b)

HXL8	P.pentandra	100.00	SEQ ID NO:1
Pp-PDF	P.pentandra	78.00	SEQ ID NO:97
HXL9	Z.mays	100.00	SEQ ID NO:9
ZmD25	Z.mays	60.00	SEQ ID NOL987
HXL12	A.retroflexus	100.00	SEQ ID NO:10
SolD1	S.oleracea	66.67	SEQ ID NO:99
HXL13	T.aestivum	100.00	SEQ ID NO:11
GmD7	G.max	95.74	SEQ ID NO:100
HXL15	O.sativa	100.00	SEQ ID NO:12
DLP322	B.distachyon	81.63	SEQ ID NO:101
OsD17	O.sativa	97.96	SEQ ID NO:102
ObD1	O.brachyantha	93.88	SEQ ID NO:103
HXL32	T.aestivum	100.00	SEQ ID NO:13
Tk-AMP-D2	A.tauschii	97.96	SEQ ID NO:104
Ta-PDF33	T.aestivum	97.96	SEQ ID NO:105
TaD19	T.aestivum	93.88	SEQ ID NO:106
rmTAD1	T.aestivum	89.80	SEQ ID NO:107
Ta-PDF30	T.aestivum	81.63	SEQ ID NO:108

Figure 1(c)

HXL33	P.argentatum	100.00	SEQ ID NO:14
HaD3	H.annuus	87.23	SEQ ID NO:109
EpD2	E.parvulum	85.11	SEQ ID NO:110
JcD1	J.curcas	82.98	SEQ ID NO:111
PgD1	P.ginseng	82.98	SEQ ID NO:112
VfoD1	V.fordii	82.98	SEQ ID NO:113
BnD9	B.napus	80.85	SEQ ID NO:114
EsD5	E.salsugineum	80.85	SEQ ID NO:115
FvD6	F.vesca	80.85	SEQ ID NO:116
JcD2	J.curcas	80.85	SEQ ID NO:117
Pa-PDF	P.argentatum	80.85	SEQ ID NO:118
RcD3	R.communis	80.85	SEQ ID NO:119
SlD20	S.lycopersicum	80.85	SEQ ID NO:120
StD13	S.tuberosum	80.85	SEQ ID NO:121
HXL34	N.benthamiana	100.00	SEQ ID NO:15
ScD1	S.chacoense	87.23	SEQ ID NO:122
SlD17	S.lycopersicum	85.11	SEQ ID NO:123
NaD2	N.alata	80.85	SEQ ID NO:124
NtD4	N.tabacum	80.85	SEQ ID NO:125

Figure 1(d)

NaD1	N.alata	100.00	SEQ ID NO:18
FST	N.tabacum	97.87	SEQ ID NO:126
NtD3	N.tabacum	95.74	SEQ ID NO:127
NeThio2	N.excelsior	93.62	SEQ ID NO:128
SL14B1	N.gossei	93.62	SEQ ID NO:129
SL78B	N.amplexicaulis	91.49	SEQ ID NO:130
NeD1	N.excelsior	91.49	SEQ ID NO:131
SL137	N.goodspeedii	91.49	SEQ ID NO:132
NsD1	N.suaveolens	91.49	SEQ ID NO:16
SL549	N.burbidgeae	89.36	SEQ ID NO:133
SL445	N.truncata	89.36	SEQ ID NO:134
SL99	N.cavicola	87.23	SEQ ID NO:135
NsD2	N.suaveolens	87.23	SEQ ID NO:17
SL446	N.truncata	87.23	SEQ ID NO:136
NpD1	N.paniculata	86.67	SEQ ID NO:137
SL548	N.burbidgeae	85.11	SEQ ID NO:138
SL97	N.cavicola	85.11	SEQ ID NO:139
SL16	N.megalosiphon	85.11	SEQ ID NO:140
SL12	N.megalosiphon	85.11	SEQ ID NO:141
SL543	N.burbidgeae	82.98	SEQ ID NO:142
SL14	N.megalosiphon	82.98	SEQ ID NO:143
NoD173	N.occidentalis	82.98	SEQ ID NO:19
SL171	N.occidentalis	80.85	SEQ ID NO:144

Dm-AMP1	D.merckii	100.00	SEQ ID NO:20
Vm-PDF	V.mespilifolia	98.00	SEQ ID NO:145
VmD1	V.mespilifolia	96.00	SEQ ID NO:146
Ds-PDF	D.sinuata	93.88	SEQ ID NO:147
Hs-PDF	H.annuus	92.00	SEQ ID NO:148
Pa-PDF	P.argentatum	92.00	SEQ ID NO:149
HaD2	H.annuus	88.00	SEQ ID NO:150
EprD1	E.prostrata	85.71	SEQ ID NO:151
PpeD5	P.pentandra	84.00	SEQ ID NO:152

Figure 1(e)



Figure 2(a)



Figure 2(b)



Figure 2(c)



Figure 2(d)



Figure 3



Figure 4

Rectified Sheet
Rule 91 (ISA/AU)


40%
35%
30%
25%
20%
15%
10%
5%
0%
Percent through nail
0
2
4
6
8
10
12
14
Day
HXL008
NaD1
HXL004
HXL012
Tavaborole
Ciclopirox
Efinaconazole

Figure 5



Figure 6


% PI positive U937 cells
60
55
50
45
40
35
30
25
20
15
10
5
0
rNaD1
HXP4
HXLO1
HXLO2
HXLO4
HXLO5
HXLO8
HXLO9
HXLO12
HXLO13

Figure 7


2.00%
1.80%
1.60%
1.40%
1.20%
1.00%
0.80%
0.60%
0.40%
0.20%
0.00%
Percent lysis
NaD1
HXL008
HXL004

Figure 8


60
50
40
30
20
10
0
Percent through nail
24 H
48 H
72 H
Water
50 mM Citrate Buffer, pH 4.0
50 mM Citrate Buffer, pH 4.0, 20% Ethanol, 0.5 mM EDTA

Figure 9


A
B
AU
0.60
0.40
0.20
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
Minutes
C
100
90
80
70
60
50
40
30
20
10
0

Figure 10


10 20 30 40 50
HXL008 KVCTKPSKFFKGLCGTDGACTTACRKEGLHSGYCQLKGFLNSVCVCRKHC SEQ ID NO:1
HXL035 KVCTKPSKFFKGLCGFDRDCTVACKKEGLASGFCQNKGFFNVVCVCRKPC SEQ ID NO:2
HXL036 KVCTKPSKFFKGLCGADRDCTVACKKEGLATGFCQKKGFFNFVCVCRKPC SEQ ID NO:3
consensus KVCTKPSKFFKGLCGxDxxCTxACxKEGLxxGxCQxKGFxNxVCVCRKxC SEQ ID NO:24

Figure 11